{"gene":"CDK2","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1992,"finding":"CDK2 activity is regulated by phosphorylation: Thr160 phosphorylation is required for kinase activity (T160A abolishes activity), while Tyr15 and Thr14 phosphorylation are inhibitory (mutation of Y15/T14 stimulates activity). CDC25 phosphatase activates CDK2 by dephosphorylating Y15/T14 in vitro.","method":"Site-directed mutagenesis, transient transfection in COS cells, in vitro phosphatase assay, cell cycle synchronization","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro assay combined with mutagenesis, replicated across multiple regulatory sites, consistent with parallel CDC2 findings","pmids":["1396589"],"is_preprint":false},{"year":1992,"finding":"CDK2 phosphorylates the retinoblastoma protein (RB) in vitro at sites phosphorylated in vivo, and CDK2 forms a complex with RB in vitro. The timing of CDK2 activation correlates with onset of RB phosphorylation in the cell cycle.","method":"In vitro kinase assay with purified CDK2, co-precipitation/complex formation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution with purified protein, site correspondence confirmed, timing correlation in cells","pmids":["1518810"],"is_preprint":false},{"year":1992,"finding":"Cyclin E and cyclin A each associate with CDK2 in a temporally distinct manner during the cell cycle: cyclin E/CDK2 appears in G1 and associates with E2F and p107, while cyclin A/CDK2 association with E2F becomes detectable as cells enter S phase.","method":"Immunoprecipitation with cyclin-specific antisera, cell cycle synchronization","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal immunoprecipitation across multiple human cell lines with cell cycle staging","pmids":["1398067"],"is_preprint":false},{"year":1992,"finding":"In Xenopus, CDK2 is regulated by periodic phosphorylation on tyrosine and serine residues during the cell cycle; CDC25 phosphatase dephosphorylates CDK2 at the major in vivo phosphorylation site and activates it in vitro.","method":"Phosphopeptide mapping, in vitro CDC25 dephosphorylation assay, immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with phosphopeptide mapping confirming site-specific dephosphorylation and activation","pmids":["1517236"],"is_preprint":false},{"year":1993,"finding":"CDK2 is required for the G1-to-S phase transition in mammalian cells; microinjection of anti-CDK2 antibodies blocked cells from entering S phase, and the effect was abrogated by pre-adsorption with CDK2 protein. Cyclin E/CDK2 complex accounts for the majority of histone H1 kinase activity in late G1.","method":"Antibody microinjection into serum-stimulated quiescent human fibroblasts, immunoprecipitation/kinase assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function by antibody microinjection with specific rescue control, corroborated by kinase activity measurements","pmids":["8502482"],"is_preprint":false},{"year":1995,"finding":"CDK2 kinase is required for activating the origin unwinding step of DNA replication; in CDK2-depleted Xenopus egg extracts, primer synthesis does not occur and RPA remains tightly associated with replication foci. Organization of chromatin into replication foci is CDK2-independent and precedes CDK2 activation.","method":"Cell-free Xenopus egg extract replication system, CDK2 immunodepletion, primer synthesis assay, RPA localization","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted cell-free system with immunodepletion and direct biochemical readouts","pmids":["7698977"],"is_preprint":false},{"year":1997,"finding":"Cyclin E/CDK2 directly phosphorylates p27Kip1 at Thr187 in vitro and in vivo, leading to p27 elimination from the cell and allowing G1-to-S progression. Mutation of T187 to alanine creates a p27 resistant to cyclin E-driven degradation. p27 interacts with cyclin E/CDK2 in two ways: as a tight inhibitor (at low ATP) or as a substrate (at physiological ATP), governed by ATP binding to CDK2.","method":"In vitro kinase assay, mutagenesis (T187A), transient expression in murine fibroblasts, cell cycle analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, kinetic analysis, and in vivo validation in multiple cellular contexts","pmids":["9192873"],"is_preprint":false},{"year":1997,"finding":"Ras and Myc cooperate to induce accumulation of active cyclin E-dependent CDK2 kinase activity and E2F target gene expression; this cooperative activation is associated with loss of the p27 CDK inhibitor. Ras alone is insufficient to induce cyclin E-CDK2 activity.","method":"Ras inhibition (dominant negative), Myc/Ras co-expression, CDK kinase assays, cell cycle analysis in Rb+/+ and Rb-/- fibroblasts","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with kinase activity measurement, single lab, multiple cell line contexts","pmids":["9163430"],"is_preprint":false},{"year":1999,"finding":"p27 acts as a tight-binding inhibitor of CDK2/Cyclin E; CDK2/Cyclin E has ~60-fold higher specificity for pRb than histone H1. The CDK2/Cyclin E/p27 ternary complex is kinetically inactive as a kinase but serves as a substrate for CDK2/Cyclin E. p27 can be phosphorylated by CDK2/Cyclin E only at high enzyme concentrations.","method":"In vitro kinase assay with purified recombinant proteins (CAK-phosphorylated CDK2/Cyclin E, p27), kcat/Km determination, inhibition kinetics","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro reconstitution with purified proteins and quantitative kinetic analysis","pmids":["10393546"],"is_preprint":false},{"year":1999,"finding":"p130 (Rb family member) directly substitutes for p27 and p21 as a CDK2 inhibitor in mitogen-starved fibroblasts; cyclin E-CDK2 kinase activity cannot be inhibited by mitogen starvation in cells lacking both p27 and p130.","method":"MEFs from p27/p21 double knockout mice, CDK2 activity assays, p130 identification as titratable CDK2 inhibitor","journal":"Current biology : CB","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic double knockout plus biochemical CDK2 activity measurement, single lab","pmids":["10074425"],"is_preprint":false},{"year":1999,"finding":"Cyclin D1 forms complexes with PCNA and CDK2 in senescent cells; excess cyclin D1 inhibits CDK2 kinase activity and represses DNA replication in vitro. Overexpression of CDK2 or PCNA rescues the cyclin D1-mediated inhibition of DNA synthesis.","method":"Co-immunoprecipitation, in vitro kinase assay (GST-cyclin D1), in vitro DNA replication assay, rescue by CDK2/PCNA overexpression","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro assay plus genetic rescue, single lab","pmids":["9925749"],"is_preprint":false},{"year":2000,"finding":"PKCη associates with the cyclin E/CDK2/p21 complex in keratinocytes, phosphorylates p21 within the complex, and inhibits CDK2 kinase activity (measured by Rb phosphorylation). This is accompanied by dephosphorylation of Thr160 on CDK2.","method":"Co-immunoprecipitation, in vitro kinase assay, dominant-negative PKCη, immunofluorescence colocalization","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with kinase assay and dominant-negative control, single lab","pmids":["11175348"],"is_preprint":false},{"year":2001,"finding":"RINGO (Speedy) activates CDK2 independently of Thr160 phosphorylation; CDK2-RINGO complexes are less susceptible to inhibition by p21 than cyclin-bound CDK2. RINGO can bind and stimulate CDK2 kinase activity without the T-loop phosphorylation required for cyclin-activated CDK2.","method":"In vitro kinase assays with RINGO-CDK2 complexes, T161A mutagenesis, p21 inhibition assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis demonstrating mechanistic independence from canonical activation pathway","pmids":["11461916"],"is_preprint":false},{"year":2003,"finding":"CDK2 knockout mice are viable but sterile; Cdk2 is required for germ cell development and meiosis. In Cdk2-/- cells, cyclin E1 immunoprecipitates show no kinase activity toward histone H1. CDK2 loss affects the timing of S phase entry but does not prevent cell proliferation, with cyclin A2 complexes maintaining activity.","method":"Gene knockout mice, immunoprecipitation/kinase assay, cell cycle analysis, MEF proliferation assays, ectopic CDK2 re-expression rescue","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — complete gene knockout with biochemical validation, rescue experiment, replicated phenotype across multiple tissues","pmids":["14561402"],"is_preprint":false},{"year":2003,"finding":"CDK2 is dispensable for proliferation in multiple cancer cell types (colon cancer, osteosarcoma, Rb-negative cervical cancers); inhibition of CDK2 by dominant-negative CDK2, antisense oligonucleotides, or siRNA did not prevent cell proliferation in these cells.","method":"Dominant-negative CDK2 expression, antisense oligonucleotides, siRNA knockdown, cell proliferation assays","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple independent loss-of-function approaches in multiple cell lines, single lab, negative finding","pmids":["12676582"],"is_preprint":false},{"year":2005,"finding":"CDK2 is a genuine client of the Hsp90/Cdc37 chaperone complex; disruption of helix αC of CDK2 disrupts Hsp90 and Cdc37 binding. The G-box motif of CDK2 is critical for Cdc37 binding, while helix αC and stabilization of helix αE are required for Hsp90 binding.","method":"Pull-down assays, Hsp90 inhibitor (geldanamycin) treatment, deletion mutagenesis, molybdate stabilization","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pull-down approaches with mutagenesis, single lab","pmids":["16285732"],"is_preprint":false},{"year":2005,"finding":"Biochemical characterization of CDK2-Speedy/Ringo A2 shows it has broad substrate specificity (unlike the canonical (S/T)PX(K/R) preference of CDK2-cyclin A), phosphorylates Cdc25 proteins nearly as well as CDK2-cyclin A at non-canonical sites, and its activity and substrate recognition are not significantly affected by Thr160 phosphorylation. CDK2-Speedy/Ringo A2 is not a substrate for metazoan CAK.","method":"In vitro kinase assays with purified proteins, phosphopeptide mapping, CAK phosphorylation assay, Thr160A mutagenesis","journal":"BMC biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro reconstitution with quantitative substrate profiling and mutagenesis","pmids":["16191191"],"is_preprint":false},{"year":2006,"finding":"Cdk2 and Cdk4 cooperate to phosphorylate Rb in vivo; Cdk2-/-Cdk4-/- double knockout mice die embryonically (~E15) with progressive reduction of Rb phosphorylation and reduced E2F-target gene expression. HPV-E7 inactivation of Rb rescues DKO MEF phenotypes (senescence, proliferation), but p27 loss does not.","method":"Double knockout mice, western blot for Rb phosphorylation, MEF proliferation/senescence assays, genetic epistasis with HPV-E7 and p27 knockout","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — double genetic knockout with epistasis rescue experiments, multiple orthogonal readouts","pmids":["16678773"],"is_preprint":false},{"year":2006,"finding":"CDK2 directly phosphorylates FOXO1 at Ser249 in vitro and in vivo, causing cytoplasmic localization and inhibition of FOXO1. This phosphorylation is abrogated upon DNA damage through the Chk1/Chk2 checkpoint pathway. CDK2-mediated inhibition of FOXO1 regulates apoptotic cell death after DNA strand breakage.","method":"In vitro kinase assay, in vivo phosphorylation, siRNA knockdown, subcellular localization assays, checkpoint kinase inhibition","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro phosphorylation with in vivo validation, localization consequence demonstrated, pathway epistasis established","pmids":["17038621"],"is_preprint":false},{"year":2007,"finding":"CDK2 is capable of autophosphorylation at Thr160; bacterially expressed monomeric CDK2 is phosphorylated at Thr160 and exhibits kinase activity toward histone H1 that is stimulated by cyclin E or A. Pharmacological CDK2 inhibition or co-expression of p21/p27 inhibits Thr160 phosphorylation in human cells.","method":"Bacterial expression/purification, mass spectrometry phosphopeptide mapping, mutagenesis (K33R, T160A), lambda phosphatase treatment, CDK2 inhibitor treatment in cells","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mass spectrometry confirmation and mutagenesis, single lab but multiple orthogonal approaches","pmids":["17361108"],"is_preprint":false},{"year":2008,"finding":"CDK2 phosphorylates SMRT transcriptional corepressor at multiple sites, creating a phosphorylation-dependent binding site for the Pin1 prolyl isomerase, which decreases SMRT protein stability and affects SMRT-dependent transcriptional repression. Her2/Neu/ErbB2 signaling functions upstream of both Pin1 and CDK2 to regulate SMRT stability.","method":"Co-immunoprecipitation (in vitro and in mammalian cells), mutagenesis of phosphorylation sites, protein stability assays","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP in vitro and in cells, mutagenesis validation, single lab","pmids":["18838553"],"is_preprint":false},{"year":2008,"finding":"Both Cdk1 and Cdk2 are necessary for efficient DNA replication in Xenopus egg extracts by controlling origin activation frequency; Cdk2/cyclin E contributes more to origin cluster efficiency than Cdk1/cyclin A. CDK activity controls the pre-replication complex to pre-initiation complex transition at low activity levels.","method":"Protein depletion and selective chemical inhibition in Xenopus egg extracts, DNA replication and origin spacing analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — cell-free reconstitution with independent depletion and chemical inhibition approaches","pmids":["18256689"],"is_preprint":false},{"year":2009,"finding":"DNA damage induces Chk1-dependent activating T160 phosphorylation of CDK2 and increases CDK2 activity; this CDK2 upregulation promotes centrosome amplification after ionizing radiation. CDK1 can substitute for CDK2 in IR-induced centrosome amplification. T160A mutation blocks CDK2-mediated rescue of centrosome amplification.","method":"CDK2-/- and Chk1-/- DT40 cells, kinase activity assays, immunofluorescence, CDK2 T160A mutagenesis, rescue experiments","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockouts with mutagenesis-based rescue, multiple cell line validation, pathway epistasis","pmids":["19838212"],"is_preprint":false},{"year":2009,"finding":"Depletion of origin licensing factors (Cdc6 or Cdt1) inhibits cyclin E/CDK2 activity in normal cells through reduction of activating T160 phosphorylation and delayed nuclear CDK2 accumulation; this Cdk2 inhibition requires p53. CDK2 activity is uncoupled from origin licensing in p53-deficient cancer cells.","method":"siRNA depletion, CDK2 kinase assay, T160 phosphorylation western blot, CDK2 subcellular fractionation, p53 co-depletion epistasis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple depletion approaches with biochemical CDK2 readouts, p53 epistasis, single lab","pmids":["19440053"],"is_preprint":false},{"year":2011,"finding":"CDK2 has a non-catalytic function in restricting assembly of cyclin A with CDK1; a sensitizing mutation in CDK2 impaired this function, which could be corrected by both inhibitory and non-inhibitory bulky adenine analogs. Chemical-genetic approach revealed CDK2 activity is required for restriction point passage and S phase entry in human cells.","method":"Chemical genetics with analog-sensitive CDK2 allele, bulky adenine analog inhibition and rescue, cell cycle analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — analog-sensitive allele approach with orthogonal chemical tools, distinguishes catalytic from non-catalytic CDK2 functions","pmids":["21658603"],"is_preprint":false},{"year":2013,"finding":"CDK2 activity bifurcates at mitotic exit to control the proliferation-quiescence decision: cells either immediately build up CDK2 activity (commit to next cycle) or suppress CDK2 activity and enter transient quiescence (G0-like state). This bifurcation is directly controlled by the CDK inhibitor p21, and regulated by mitogens during a restriction window at the end of the previous cell cycle.","method":"Live-cell CDK2 activity sensor, single-cell imaging, p21 manipulation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — live-cell CDK2 biosensor with loss-of-function validation, mechanistic pathway placement","pmids":["24075009"],"is_preprint":false},{"year":2014,"finding":"CDK2 ablation combined with cyclin A2 loss strongly suppresses tumor formation in oncogene-transformed MEFs, associated with decreased proliferation, premature senescence, and failure of compensatory Cdk1 activity increase (which occurs with cyclin A2 loss alone).","method":"Conditional double knockout mice, oncogene-transformed MEF tumor formation assays, Cdk1 kinase activity measurement","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional double genetic knockout with tumor assay and compensatory kinase measurement, single lab","pmids":["24802190"],"is_preprint":false},{"year":2014,"finding":"CDK2 is required for nuclear envelope dynamics and telomere attachment during mouse meiotic prophase I; CDK2 ablation causes abnormal distribution of SUN1, KASH5, and lamin C2 in spermatocytes, and some telomeres fail to attach to the nuclear envelope. Mouse testis CDK2 phosphorylates SUN1 in vitro.","method":"Immunofluorescence and electron microscopy of Cdk2-/- spermatocytes, in vitro kinase assay with SUN1 substrate","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout phenotype with in vitro kinase substrate validation, single lab","pmids":["25380821"],"is_preprint":false},{"year":2015,"finding":"Wild-type CDK2 can bind type II inhibitors that target the DFG-out (inactive) conformation; type II inhibitors compete with binding of activating cyclins to CDK2. Key residues distant from the ATP-binding pocket modulate the energetics of the DFG-out transition.","method":"Site-directed mutagenesis, protein crystallography (first CDK2/type II inhibitor co-crystal structure), biochemical/biophysical inhibitor binding assays","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis and binding kinetics, demonstrates novel inhibitor binding mode","pmids":["26158339"],"is_preprint":false},{"year":2015,"finding":"An irreversible CDK2 inhibitor (NU6300) binds covalently to CDK2, confirmed by co-complex crystal structure. Acute treatment produced durable inhibition of Rb phosphorylation in cells, consistent with irreversible CDK2 inhibition.","method":"Crystal structure of CDK2/NU6300 covalent complex, cell-based Rb phosphorylation assay","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure of covalent complex with cellular validation, single lab","pmids":["26320860"],"is_preprint":false},{"year":2016,"finding":"CDK2 catalytic activity is essential for meiotic cell division in vivo; kinase-dead CDK2 knockin mice (D145N or T160A) are sterile with defective meiosis, identical to Cdk2 knockout mice. These point mutant mice show normal mitotic cell cycle progression, demonstrating the meiotic function is specifically kinase-activity-dependent.","method":"Knockin mouse generation (D145N, T160A point mutations), phenotypic analysis, cell cycle analysis in MEFs, reproductive organ analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent kinase-dead knockin alleles with identical meiotic sterility phenotype, distinguishes catalytic from non-catalytic functions","pmids":["27371320"],"is_preprint":false},{"year":2019,"finding":"CDK2 has a non-canonical role in regulating neutrophil migration and cell polarity, independent of its cell cycle functions; CDK2 inhibition or knockdown disrupts neutrophil chemotaxis and polarization without inducing cell death, and alters downstream formyl peptide receptor signaling in terminally differentiated neutrophils.","method":"miRNA screen in zebrafish, CDK2 inhibition and siRNA knockdown in zebrafish and human neutrophil-like cells, chemotaxis assay, cell polarity imaging","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple loss-of-function approaches in two model systems with defined cellular phenotype, single lab","pmids":["31451657"],"is_preprint":false},{"year":2019,"finding":"CDK1 and CDK2 phosphorylate Notch intracellular domain (NICD1) in a domain required for SCF E3 ligase recognition; inhibiting CDK1 or CDK2 increases NICD1 levels in vitro and in vivo and delays segmentation clock oscillation period.","method":"In vitro kinase assay with CDK1 and CDK2, CDK inhibitor treatment in vivo, NICD1 protein level measurement, clock period analysis","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay combined with in vivo CDK inhibitor effects, single lab","pmids":["31267714"],"is_preprint":false},{"year":2020,"finding":"CDK2 localizes to late recombination nodules (LRNs) at meiotic crossover sites; elevated CDK2 activity increases MLH1 focus numbers at LRNs but not crossover numbers, while reduced CDK2 activity abolishes crossover formation entirely during meiotic prophase I.","method":"CDK2 activity point mutant knockin mice (elevated/reduced activity), immunofluorescence of LRN proteins, crossover analysis","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two activity-modulating knockin alleles with quantitative meiotic phenotype analysis, single lab","pmids":["33075054"],"is_preprint":false},{"year":2021,"finding":"Allosteric coupling between CDK2 regulatory phosphorylation (Thr160) and cyclin binding explains CDK2 activation; monomeric CDK2 samples an active-like state but lacks activity; T-loop phosphorylation enhances allosteric coupling with cyclin. An allosteric hub diverged between CDK2 and CDK4 governs the strength of allosteric coupling and differential inhibitor recognition.","method":"Solution biophysics, thermodynamic modeling, NMR/EPR spectroscopy, functional assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple biophysical methods with thermodynamic modeling establish allosteric mechanism of CDK2 activation","pmids":["33526892"],"is_preprint":false},{"year":2022,"finding":"Mitochondrial ROS promote CDK2 T-loop (Thr160) phosphorylation and full CDK2 activation during S phase by oxidizing a conserved cysteine residue near the T-loop, which prevents binding of the T-loop phosphatase KAP, thereby coupling mitochondrial metabolism to DNA replication via CDK2.","method":"Chemical/metabolic ROS interference, live-cell CDK2 activity reporters, phosphorylation assays, cysteine mutagenesis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal interference methods with mechanistic identification of cysteine oxidation preventing KAP binding","pmids":["35809563"],"is_preprint":false},{"year":2022,"finding":"Disrupting the CDK2/Cyclin A protein-protein interaction (PPI) with homoharringtonine (HHT) induces autophagic degradation of CDK2 via Trim21 E3 ubiquitin ligase in cancer cells, confirmed in a leukemia mouse model.","method":"In silico PPI pocket screening, protein interaction disruption assay, CDK2 degradation assay, Trim21 identification, leukemia mouse model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — PPI disruption with identification of E3 ligase mediating CDK2 autophagic degradation, validated in mouse model, single lab","pmids":["35595767"],"is_preprint":false},{"year":2022,"finding":"CDK2 inhibition reduces RB phosphorylation, decreases E2F-mediated DNMT1 transcription, and increases endogenous retroviral RNA expression and type I IFN response, enhancing antitumor immunity through increased antigen presentation and CD8+ T-cell infiltration.","method":"CDK2 small molecule inhibitors, genetic Cdk2 deficiency in murine tumor models, IFN response measurement, T-cell infiltration analysis","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological CDK2 loss-of-function with mechanistic pathway (RB→E2F→DNMT1→ERV→IFN), single lab","pmids":["35181784"],"is_preprint":false},{"year":2022,"finding":"WEE1 kinase protects stalled DNA replication forks by suppressing CDK2 activity; CDK2 suppression is the major WEE1-dependent activity counteracting fork degradation, and DNA2 nuclease is responsible for excessive fork degradation in WEE1-inhibited cells.","method":"WEE1 inhibition, CDK2 inhibition, DNA fiber assays, DNA2 knockdown epistasis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis between WEE1, CDK2, and DNA2 with defined fork degradation phenotype, single lab","pmids":["35045293"],"is_preprint":false},{"year":2022,"finding":"SARS-CoV-2 nsp12 (RdRp) interacts with host CDK2; CDK2 phosphorylates nsp12 at Thr20, facilitating assembly of the RdRp complex (nsp12/nsp7/nsp8) and promoting viral RNA synthesis. CDK2 inhibitors impair viral RNA synthesis and SARS-CoV-2 infection.","method":"Mass spectrometry-based proteomics, Co-IP, in vitro phosphorylation assay, CDK2 inhibitor treatment, viral RNA measurement","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vitro phosphorylation with functional viral RNA readout, single lab","pmids":["36575184"],"is_preprint":false},{"year":2023,"finding":"Upon acute CDK2 inhibition, CDK4/6 activity backstops CDK2 by maintaining Rb1 hyperphosphorylation, active E2F transcription, and cyclin A2 expression, enabling re-activation of CDK2 in the presence of drug. CDK1 does not compensate for acute CDK2 inhibition (unlike in Cdk2-/- mice). Co-inhibition of CDK2 and CDK4/6 is required to suppress adaptation.","method":"Multiple CDK2 inhibitors, phosphoproteomics of CDK2 substrates, cell cycle analysis, combination drug treatment","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple CDK2 inhibitors with phosphoproteomic substrate tracking and genetic/pharmacological epistasis, mechanistic drug adaptation pathway defined","pmids":["37267950"],"is_preprint":false},{"year":2023,"finding":"Type III allosteric CDK2 inhibitors (anthranilic acid series) bind CDK2 with nanomolar affinity and exhibit strong negative cooperativity with cyclin binding, providing CDK2 selectivity over CDK1. These inhibitors recapitulate Cdk2-/- meiotic phenotypes in testicular explants.","method":"Crystal structure, biophysical binding assays, cellular CDK2 activity assays, mouse testicular explant phenotypic assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure confirming allosteric binding mode, biophysical cooperativity measurements, in vitro and ex vivo functional validation","pmids":["37270540"],"is_preprint":false},{"year":2011,"finding":"Endosomal CDK2 associates with SHP-1 phosphatase and β-catenin in hepatic endosome fractions; CDK2 phosphorylates β-catenin (but not CEACAM1), and partial CDK2 downmodulation increases insulin internalization rate, placing CDK2 in a Cdk2/SHP-1/β-catenin/CEACAM1 axis regulating insulin internalization.","method":"Subcellular fractionation, Triton X-100 resistance assay, co-immunoprecipitation, CDK2 knockdown, insulin internalization assay","journal":"Cellular signalling","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP plus knockdown with functional readout, substrate assignment not fully confirmed by in vitro reconstitution, single lab","pmids":["21262353"],"is_preprint":false},{"year":2009,"finding":"CAC1 (Cdk-Associated Cullin1), a novel cullin-domain protein, physically associates with CDK2 and promotes CDK2 kinase activity; CAC1 knockdown by RNAi inhibits cell proliferation and induces G1/S arrest.","method":"Co-immunoprecipitation, CDK2 kinase activity assay after CAC1 knockdown, RNAi, cell cycle analysis","journal":"Cell cycle (Georgetown, Tex.)","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP and kinase assay, mechanism of CDK2 activation by CAC1 not fully characterized, single lab","pmids":["19829063"],"is_preprint":false},{"year":2016,"finding":"CDK2/Cyclin E and CDK2/Cyclin A phosphorylate ING5 at Thr152 in vitro; this phosphorylation occurs in cells in a cell cycle-dependent manner, and is enhanced by cyclin E/CDK2 overexpression and repressed by p27KIP1.","method":"In vitro kinase assay, phosphosite mutagenesis, cell cycle-dependent phosphorylation analysis, CDK2/cyclin overexpression and p27 inhibition","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis confirmed in cells, single lab","pmids":["25860957"],"is_preprint":false},{"year":2016,"finding":"CDK2/Cyclin E phosphorylates CK1δ at its C-terminal domain, and this phosphorylation reduces CK1δ activity in vitro; pre-incubation of CK1δ with CDK2/E reduces CK1δ activity, and CDK inhibition with dinaciclib increases CK1δ activity in pancreatic cancer cells.","method":"In vitro kinase assay, CK1δ activity assay after CDK2/E phosphorylation, CDK inhibitor treatment in cells","journal":"Amino acids","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — in vitro phosphorylation with activity consequence validated in cells, single lab","pmids":["26464264"],"is_preprint":false},{"year":2019,"finding":"CDK2 phosphorylates c-Myc at Serine 62 at the beginning of S phase, promoting c-Myc association with the miR-571 promoter and suppressing miR-571 expression to prevent aberrant DNA rereplication; this Cdk2-c-Myc-miR-571 axis regulates DNA replication and genomic stability.","method":"ChIP assay, c-Myc phospho-Ser62 detection, miR-571 promoter reporter, CDK2 inhibition and overexpression","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple approaches linking CDK2 phosphorylation of c-Myc to promoter binding and miRNA regulation, single lab","pmids":["31431461"],"is_preprint":false}],"current_model":"CDK2 is a serine/threonine kinase that requires binding of a cyclin (E or A) and activating phosphorylation at Thr160 (by CAK or autocatalysis) for full activity, while inhibitory phosphorylation at Thr14/Tyr15 (reversed by CDC25 phosphatases) suppresses it; the cyclin E/CDK2 complex drives G1/S transition by phosphorylating RB and p27 (at T187, targeting it for degradation), while cyclin A/CDK2 promotes S phase and DNA replication, and CDK2 activity is additionally regulated by the CDK inhibitors p21 and p27, by allosteric coupling between the T-loop and cyclin binding, by ROS-mediated oxidation of a conserved cysteine that prevents KAP phosphatase binding, and by the Hsp90/Cdc37 chaperone complex; CDK2 is non-redundantly required for meiosis (through its kinase activity) via roles in telomere–nuclear envelope attachment and meiotic crossover formation, and has non-canonical roles including phosphorylation of FOXO1 (linking DNA damage to apoptosis), SMRT, SUN1, NICD1, c-Myc (Ser62), and ING5, regulation of neutrophil migration, and control of endosomal insulin internalization."},"narrative":{"mechanistic_narrative":"CDK2 is a cyclin-dependent serine/threonine kinase that drives the G1-to-S transition and DNA replication in the mammalian cell cycle [PMID:8502482, PMID:7698977]. Its activity requires association with cyclin E (in G1) or cyclin A (at S-phase entry) and is gated by phosphorylation: activating phosphorylation at Thr160 — installed by autophosphorylation or chaperone-assisted maturation as an Hsp90/Cdc37 client [PMID:17361108, PMID:16285732] — is required for catalysis, while inhibitory Thr14/Tyr15 phosphorylation suppresses it and is reversed by CDC25 phosphatase [PMID:1396589, PMID:1517236]. Activation reflects allosteric coupling between T-loop phosphorylation and cyclin binding, with monomeric CDK2 sampling an active-like but inactive state until cyclin engagement strengthens this coupling [PMID:33526892]. Once active, cyclin E/CDK2 phosphorylates the retinoblastoma protein to relieve E2F repression and phosphorylates p27Kip1 at Thr187 to trigger its degradation, coupling mitogenic signaling to S-phase commitment [PMID:1518810, PMID:9192873, PMID:1398067]; CDK2 activity at the licensed origin is required for origin unwinding and primer synthesis [PMID:7698977, PMID:18256689]. CDK2 activity is held in check by the CIP/KIP inhibitors p21 and p27, which can act either as tight-binding inhibitors or substrates depending on enzyme and ATP levels, and the level of CDK2 activity at mitotic exit — set by p21 — bifurcates cells into proliferation or quiescence [PMID:10393546, PMID:9192873, PMID:24075009]. CDK2 is non-redundant for meiosis: kinase-dead knockin mice are sterile with intact mitosis, and CDK2 controls telomere–nuclear envelope attachment (phosphorylating SUN1) and meiotic crossover formation at late recombination nodules [PMID:27371320, PMID:25380821, PMID:33075054]. Beyond the canonical cycle, CDK2 phosphorylates a range of substrates including FOXO1 (linking DNA damage to apoptotic control), c-Myc at Ser62, SMRT, NICD1, ING5 and CK1δ, and has cell-cycle-independent roles in neutrophil chemotaxis [PMID:17038621, PMID:31431461, PMID:18838553, PMID:31267714, PMID:31451657]. CDK2 is largely dispensable for proliferation of many cancer cells because CDK1, CDK4/6, and cyclin A redundancy can compensate, a redundancy that also underlies adaptation to CDK2 inhibitors [PMID:12676582, PMID:16678773, PMID:37267950].","teleology":[{"year":1992,"claim":"Established how CDK2 catalytic output is switched on and off, defining the dual phosphorylation logic that gates a cell-cycle kinase.","evidence":"Site-directed mutagenesis and in vitro phosphatase assays in human and Xenopus systems mapping activating Thr160 and inhibitory Thr14/Tyr15 sites reversed by CDC25","pmids":["1396589","1517236"],"confidence":"High","gaps":["Did not identify the activating Thr160 kinase (CAK) in these experiments","Upstream control of CDC25 toward CDK2 not addressed"]},{"year":1992,"claim":"Connected CDK2 to the RB/E2F machinery and showed cyclin E versus cyclin A partner cyclins act in temporally distinct windows, placing CDK2 at the G1/S control point.","evidence":"In vitro kinase assays with purified CDK2 against RB and cell-cycle-staged immunoprecipitation of cyclin E/A complexes with E2F/p107","pmids":["1518810","1398067"],"confidence":"High","gaps":["Causal requirement for CDK2 in vivo not yet demonstrated","Functional consequence of RB phosphorylation on E2F release not shown here"]},{"year":1993,"claim":"Demonstrated CDK2 is functionally required for entry into S phase, moving it from correlation to causation.","evidence":"Microinjection of anti-CDK2 antibodies into quiescent fibroblasts with antigen pre-adsorption rescue and kinase activity measurement","pmids":["8502482"],"confidence":"High","gaps":["Does not distinguish cyclin E from cyclin A complex contributions","Critical S-phase substrates not identified"]},{"year":1995,"claim":"Defined the specific replication step requiring CDK2, showing it acts at origin unwinding/initiation rather than chromatin organization.","evidence":"CDK2 immunodepletion in Xenopus egg extracts with primer synthesis and RPA localization readouts","pmids":["7698977"],"confidence":"High","gaps":["Direct replication-machinery substrates of CDK2 not identified","Relative contribution of CDK1 not addressed in this study"]},{"year":1997,"claim":"Resolved how CDK2 escapes its own inhibitor, establishing the feed-forward p27-Thr187 phosphodegron and the substrate-versus-inhibitor duality of CIP/KIP proteins.","evidence":"In vitro kinase assays with T187A mutagenesis, ATP-dependent kinetics, and expression in fibroblasts; Ras/Myc cooperation linked to p27 loss and CDK2 activation","pmids":["9192873","9163430"],"confidence":"High","gaps":["E3 ligase mediating p27 degradation not characterized here","Mechanism of the ATP-dependent inhibitor-to-substrate switch left open"]},{"year":1999,"claim":"Quantified CDK2 substrate preference and inhibitor stoichiometry, and identified redundant inhibitors (p130, cyclin D1) that buffer CDK2 activity.","evidence":"In vitro kinetics with purified CAK-phosphorylated CDK2/cyclin E, p27 inhibition assays, p27/p21 double-knockout MEFs, and cyclin D1/PCNA co-IP","pmids":["10393546","10074425","9925749"],"confidence":"High","gaps":["Physiological relevance of cyclin D1-CDK2-PCNA complex limited to senescent context","Redundancy hierarchy among inhibitors in normal cells unresolved"]},{"year":2001,"claim":"Revealed that CDK2 can be activated through a non-canonical, Thr160-independent route, expanding the modes of CDK2 control.","evidence":"In vitro reconstitution of RINGO/Speedy–CDK2 complexes with T-loop mutagenesis and p21 inhibition assays; later substrate profiling showed broad specificity and CAK independence","pmids":["11461916","16191191"],"confidence":"High","gaps":["In vivo contexts where RINGO activation dominates not defined","Endogenous RINGO–CDK2 substrate set in cells not mapped"]},{"year":2003,"claim":"Genetic ablation overturned the view of CDK2 as essential for the mitotic cycle, revealing dispensability for proliferation but absolute requirement for meiosis.","evidence":"Cdk2 knockout mice and cancer-cell loss-of-function (dominant-negative, antisense, siRNA) with kinase and proliferation assays","pmids":["14561402","12676582"],"confidence":"High","gaps":["Molecular basis of compensation not yet identified in 2003","Meiotic substrates of CDK2 not defined"]},{"year":2006,"claim":"Identified the compensating kinases and a DNA-damage-linked substrate, explaining CDK2 redundancy in mitosis and a non-canonical apoptotic role.","evidence":"Cdk2/Cdk4 double-knockout mice with RB phosphorylation and E2F readouts plus HPV-E7/p27 epistasis; in vitro and in vivo FOXO1-Ser249 phosphorylation with checkpoint epistasis","pmids":["16678773","17038621"],"confidence":"High","gaps":["Quantitative apportioning of RB phosphorylation between CDK2 and CDK4 unclear","How Chk1/Chk2 suppress CDK2 toward FOXO1 mechanistically not detailed"]},{"year":2008,"claim":"Showed CDK2 controls replication origin activation frequency in concert with CDK1 and extended the substrate repertoire to transcriptional corepressors.","evidence":"Depletion and chemical inhibition in Xenopus egg extracts with origin spacing analysis; SMRT phosphorylation creating Pin1 docking sites by co-IP and mutagenesis","pmids":["18256689","18838553"],"confidence":"High","gaps":["Direct origin-firing substrates of CDK2 not identified","Generality of SMRT regulation across cell types untested"]},{"year":2009,"claim":"Linked CDK2 T160 activation to genome-surveillance signals — DNA damage, origin licensing, and p53 — establishing checkpoint-coupled control of CDK2.","evidence":"CDK2-/- and Chk1-/- DT40 cells with T160A rescue (centrosome amplification); siRNA depletion of licensing factors with p53 epistasis and CDK2 kinase/fractionation readouts; CAC1 co-IP","pmids":["19838212","19440053","19829063"],"confidence":"Medium","gaps":["CAC1-CDK2 activation mechanism is a single Co-IP without reconstitution","How licensing status is transduced to T160 phosphorylation not resolved"]},{"year":2011,"claim":"Distinguished catalytic from non-catalytic CDK2 functions and uncovered an endosomal signaling role, broadening CDK2 beyond a cell-cycle kinase.","evidence":"Analog-sensitive CDK2 allele with bulky adenine analogs for restriction-point passage and CDK1/cyclin A restriction; endosomal fractionation/Co-IP and knockdown for the SHP-1/β-catenin insulin-internalization axis","pmids":["21658603","21262353"],"confidence":"Medium","gaps":["β-catenin substrate assignment rests on Co-IP and knockdown without in vitro reconstitution (Low-confidence endosomal arm)","Structural basis of the non-catalytic cyclin A/CDK1 restriction function unknown"]},{"year":2016,"claim":"Demonstrated that CDK2 catalytic activity, not the protein per se, drives meiosis and identified additional cell-cycle substrates.","evidence":"Kinase-dead (D145N, T160A) knockin mice with meiotic sterility but normal mitosis; in vitro/in-cell phosphorylation of ING5-Thr152 and CK1δ","pmids":["27371320","25860957","26464264"],"confidence":"High","gaps":["Meiotic substrates accounting for sterility not fully enumerated","Physiological impact of ING5/CK1δ phosphorylation in normal tissues limited"]},{"year":2014,"claim":"Defined CDK2's role in the proliferation-quiescence decision and showed its loss, combined with cyclin A2, suppresses tumorigenesis.","evidence":"Live-cell CDK2 activity sensor with single-cell imaging and p21 manipulation; conditional Cdk2/cyclin A2 double knockout in oncogene-transformed MEF tumor assays","pmids":["24075009","26464264","24802190"],"confidence":"High","gaps":["Upstream determinants of the bifurcation beyond p21 not fully mapped","Whether the quiescence decision involves the same substrates as proliferation unclear"]},{"year":2021,"claim":"Provided the biophysical mechanism of CDK2 activation and metabolic coupling, explaining how cyclin binding, T160 phosphorylation, and redox state converge on activity.","evidence":"Solution biophysics, NMR/EPR and thermodynamic modeling of allosteric T-loop/cyclin coupling; ROS/cysteine-oxidation interference with live-cell CDK2 reporters showing blockade of KAP phosphatase binding","pmids":["33526892","35809563"],"confidence":"High","gaps":["In vivo significance of the allosteric hub divergence between CDK2/CDK4 not tested functionally","Source and timing of the S-phase ROS signal not fully defined"]},{"year":2022,"claim":"Expanded CDK2 into replication-stress, immune, and host-pathogen contexts and revealed its targetability through PPI disruption and degradation.","evidence":"WEE1/CDK2/DNA2 epistasis by DNA fiber assays; CDK2-RB-E2F-DNMT1-ERV-IFN pathway via genetic/pharmacological loss; CDK2 phosphorylation of SARS-CoV-2 nsp12-Thr20; HHT-induced Trim21-mediated autophagic CDK2 degradation; c-Myc-Ser62/miR-571 axis","pmids":["35045293","35181784","36575184","35595767","31431461"],"confidence":"Medium","gaps":["Several substrate/pathway assignments derive from single labs without reciprocal validation","Direct fork-protection substrate downstream of CDK2 not identified"]},{"year":2023,"claim":"Resolved how cells adapt to CDK2 inhibition and validated allosteric, cyclin-cooperative inhibitors with CDK2 selectivity.","evidence":"Multiple CDK2 inhibitors with substrate phosphoproteomics showing CDK4/6 backstopping; crystal structures of type II, covalent, and type III allosteric inhibitors with cooperativity measurements and testicular-explant phenotyping","pmids":["37267950","26158339","26320860","37270540"],"confidence":"High","gaps":["Durability of combination CDK2/CDK4/6 inhibition in vivo not fully established","Selectivity determinants against CDK1 only partially mapped"]},{"year":null,"claim":"The full set of physiological CDK2 substrates underlying its non-redundant meiotic function and its cell-cycle-independent roles (e.g., neutrophil migration) remains to be defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Meiotic crossover and telomere-attachment substrates beyond SUN1 not enumerated","Mechanism by which CDK2 controls neutrophil polarity/FPR signaling unknown","How context selects canonical versus non-canonical CDK2 substrate sets unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,6,18,27,32,44,45,46]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,6,19]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[6,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[23,27]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[42]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[33]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,25,24]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[5,21,38]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[13,30,33]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[18,22]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,2,20]}],"complexes":["cyclin E/CDK2","cyclin A/CDK2","Hsp90/Cdc37 chaperone complex"],"partners":["CCNE1","CCNA2","CDKN1B","CDKN1A","RB1","CDC25","CDC37","HSP90"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P24941","full_name":"Cyclin-dependent kinase 2","aliases":["Cell division protein kinase 2","p33 protein kinase"],"length_aa":298,"mass_kda":33.9,"function":"Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis (PubMed:10499802, PubMed:10884347, PubMed:10995386, PubMed:10995387, PubMed:11051553, PubMed:11113184, PubMed:12944431, PubMed:15800615, PubMed:17495531, PubMed:19966300, PubMed:20935635, PubMed:21262353, PubMed:21596315, PubMed:28216226, PubMed:28666995). Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2 (PubMed:10499802, PubMed:10995386, PubMed:10995387, PubMed:11051553, PubMed:11113184, PubMed:12944431, PubMed:15800615, PubMed:19966300, PubMed:20935635, PubMed:21262353, PubMed:21596315, PubMed:24728993, PubMed:28216226). Triggers duplication of centrosomes and DNA (PubMed:11051553). Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus (PubMed:18372919, PubMed:19238148, PubMed:19561645). Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in embryonic stem cells (ESCs) (PubMed:18372919, PubMed:19238148, PubMed:19561645). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase (PubMed:18372919, PubMed:19238148, PubMed:19561645). EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing (PubMed:20935635). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC (PubMed:19966300). Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis (PubMed:15800615, PubMed:20195506, PubMed:21319273). In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation (PubMed:15800615). Involved in regulation of telomere repair by mediating phosphorylation of NBN (PubMed:28216226). Phosphorylation of RB1 disturbs its interaction with E2F1 (PubMed:10499802). NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication (PubMed:11051553). Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase (PubMed:10995386, PubMed:10995387). Required for vitamin D-mediated growth inhibition by being itself inactivated (PubMed:20147522). Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner (PubMed:20079829). USP37 is activated by phosphorylation and thus triggers G1-S transition (PubMed:21596315). CTNNB1 phosphorylation regulates insulin internalization (PubMed:21262353). Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability (By similarity). Phosphorylates ERCC6 which is essential for its chromatin remodeling activity at DNA double-strand breaks (PubMed:29203878). Acts as a regulator of the phosphatidylinositol 3-kinase/protein kinase B signal transduction by mediating phosphorylation of the C-terminus of protein kinase B (PKB/AKT1 and PKB/AKT2), promoting its activation (PubMed:24670654)","subcellular_location":"Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Nucleus, Cajal body; Cytoplasm; Endosome","url":"https://www.uniprot.org/uniprotkb/P24941/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CDK2","classification":"Common Essential","n_dependent_lines":909,"n_total_lines":1208,"dependency_fraction":0.7524834437086093},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000123374","cell_line_id":"CID001148","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"cytoplasmic","grade":1},{"compartment":"nuclear_punctae","grade":1}],"interactors":[{"gene":"CCNA2","stoichiometry":4.0},{"gene":"CDKN1B","stoichiometry":0.2},{"gene":"CCNB1","stoichiometry":0.2},{"gene":"RBL1","stoichiometry":0.2},{"gene":"CCNE1","stoichiometry":0.2},{"gene":"SKP2","stoichiometry":0.2},{"gene":"RBL2","stoichiometry":0.2},{"gene":"CCNE2","stoichiometry":0.2},{"gene":"CSNK2A1","stoichiometry":0.2},{"gene":"CSNK2A2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001148","total_profiled":1310},"omim":[{"mim_id":"621044","title":"RING FINGER PROTEIN 157; RNF157","url":"https://www.omim.org/entry/621044"},{"mim_id":"620395","title":"CYCLIN J; CCNJ","url":"https://www.omim.org/entry/620395"},{"mim_id":"620226","title":"UBIQUITIN-SPECIFIC PEPTIDASE 37; USP37","url":"https://www.omim.org/entry/620226"},{"mim_id":"620061","title":"CDK2-ASSOCIATED PROTEIN 2; CDK2AP2","url":"https://www.omim.org/entry/620061"},{"mim_id":"619066","title":"ZINC FINGER PROTEIN 532; ZNF532","url":"https://www.omim.org/entry/619066"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"},{"location":"Centrosome","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"},{"location":"Calyx","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDK2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P24941","domains":[{"cath_id":"3.30.200.20","chopping":"3-80","consensus_level":"high","plddt":83.6264,"start":3,"end":80},{"cath_id":"1.10.510.10","chopping":"85-285","consensus_level":"high","plddt":89.9473,"start":85,"end":285}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P24941","model_url":"https://alphafold.ebi.ac.uk/files/AF-P24941-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P24941-F1-predicted_aligned_error_v6.png","plddt_mean":88.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDK2","jax_strain_url":"https://www.jax.org/strain/search?query=CDK2"},"sequence":{"accession":"P24941","fasta_url":"https://rest.uniprot.org/uniprotkb/P24941.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P24941/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P24941"}},"corpus_meta":[{"pmid":"26861625","id":"PMC_26861625","title":"Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26861625","citation_count":1370,"is_preprint":false},{"pmid":"9192873","id":"PMC_9192873","title":"Cyclin E-CDK2 is a regulator of p27Kip1.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9192873","citation_count":802,"is_preprint":false},{"pmid":"1396589","id":"PMC_1396589","title":"Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1396589","citation_count":627,"is_preprint":false},{"pmid":"14561402","id":"PMC_14561402","title":"Cdk2 knockout mice are viable.","date":"2003","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/14561402","citation_count":572,"is_preprint":false},{"pmid":"24075009","id":"PMC_24075009","title":"The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit.","date":"2013","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/24075009","citation_count":561,"is_preprint":false},{"pmid":"1398067","id":"PMC_1398067","title":"Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner.","date":"1992","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1398067","citation_count":456,"is_preprint":false},{"pmid":"12676582","id":"PMC_12676582","title":"Proliferation of cancer cells despite CDK2 inhibition.","date":"2003","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/12676582","citation_count":424,"is_preprint":false},{"pmid":"9163430","id":"PMC_9163430","title":"Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9163430","citation_count":416,"is_preprint":false},{"pmid":"8502482","id":"PMC_8502482","title":"The cdk2 kinase is required for the G1-to-S transition in mammalian cells.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8502482","citation_count":338,"is_preprint":false},{"pmid":"17038621","id":"PMC_17038621","title":"CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/17038621","citation_count":293,"is_preprint":false},{"pmid":"31839441","id":"PMC_31839441","title":"Targeting CDK2 in cancer: challenges and opportunities for therapy.","date":"2019","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/31839441","citation_count":248,"is_preprint":false},{"pmid":"1518810","id":"PMC_1518810","title":"Phosphorylation of the retinoblastoma protein by cdk2.","date":"1992","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1518810","citation_count":227,"is_preprint":false},{"pmid":"34901021","id":"PMC_34901021","title":"Cyclin E/CDK2: DNA Replication, Replication Stress and Genomic Instability.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34901021","citation_count":210,"is_preprint":false},{"pmid":"21233845","id":"PMC_21233845","title":"MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/21233845","citation_count":127,"is_preprint":false},{"pmid":"16678773","id":"PMC_16678773","title":"Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation.","date":"2006","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/16678773","citation_count":126,"is_preprint":false},{"pmid":"37267950","id":"PMC_37267950","title":"Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity.","date":"2023","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/37267950","citation_count":119,"is_preprint":false},{"pmid":"38297099","id":"PMC_38297099","title":"Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy.","date":"2024","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38297099","citation_count":114,"is_preprint":false},{"pmid":"9426687","id":"PMC_9426687","title":"Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9426687","citation_count":114,"is_preprint":false},{"pmid":"33664520","id":"PMC_33664520","title":"Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33664520","citation_count":112,"is_preprint":false},{"pmid":"15617830","id":"PMC_15617830","title":"Cdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15617830","citation_count":107,"is_preprint":false},{"pmid":"10074425","id":"PMC_10074425","title":"A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.","date":"1999","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10074425","citation_count":105,"is_preprint":false},{"pmid":"24802190","id":"PMC_24802190","title":"Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24802190","citation_count":100,"is_preprint":false},{"pmid":"19383288","id":"PMC_19383288","title":"Mice thrive without Cdk4 and Cdk2.","date":"2007","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19383288","citation_count":97,"is_preprint":false},{"pmid":"29514916","id":"PMC_29514916","title":"CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29514916","citation_count":95,"is_preprint":false},{"pmid":"35595767","id":"PMC_35595767","title":"Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35595767","citation_count":89,"is_preprint":false},{"pmid":"35809563","id":"PMC_35809563","title":"A ROS-dependent mechanism promotes CDK2 phosphorylation to drive progression through S phase.","date":"2022","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/35809563","citation_count":87,"is_preprint":false},{"pmid":"26320860","id":"PMC_26320860","title":"Identification and Characterization of an Irreversible Inhibitor of CDK2.","date":"2015","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/26320860","citation_count":87,"is_preprint":false},{"pmid":"26158339","id":"PMC_26158339","title":"Type II Inhibitors Targeting CDK2.","date":"2015","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26158339","citation_count":85,"is_preprint":false},{"pmid":"8622674","id":"PMC_8622674","title":"p21 Disrupts the interaction between cdk2 and the E2F-p130 complex.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8622674","citation_count":79,"is_preprint":false},{"pmid":"16258277","id":"PMC_16258277","title":"Cell cycle sibling rivalry: Cdc2 vs. Cdk2.","date":"2005","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16258277","citation_count":77,"is_preprint":false},{"pmid":"11461916","id":"PMC_11461916","title":"Differential regulation of Cdc2 and Cdk2 by RINGO and cyclins.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11461916","citation_count":75,"is_preprint":false},{"pmid":"28665315","id":"PMC_28665315","title":"MYC Modulation around the CDK2/p27/SKP2 Axis.","date":"2017","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/28665315","citation_count":73,"is_preprint":false},{"pmid":"21658603","id":"PMC_21658603","title":"Switching Cdk2 on or off with small molecules to reveal requirements in human cell proliferation.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21658603","citation_count":73,"is_preprint":false},{"pmid":"16618755","id":"PMC_16618755","title":"Discovery and evaluation of dual CDK1 and CDK2 inhibitors.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16618755","citation_count":72,"is_preprint":false},{"pmid":"15122251","id":"PMC_15122251","title":"Bioluminescent imaging of Cdk2 inhibition in vivo.","date":"2004","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15122251","citation_count":72,"is_preprint":false},{"pmid":"29511348","id":"PMC_29511348","title":"Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29511348","citation_count":71,"is_preprint":false},{"pmid":"7698977","id":"PMC_7698977","title":"An analysis of the regulation of DNA synthesis by cdk2, Cip1, and licensing factor.","date":"1995","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7698977","citation_count":70,"is_preprint":false},{"pmid":"32415712","id":"PMC_32415712","title":"Development of CDK2 and CDK5 Dual Degrader TMX-2172.","date":"2020","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/32415712","citation_count":63,"is_preprint":false},{"pmid":"29044141","id":"PMC_29044141","title":"Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29044141","citation_count":63,"is_preprint":false},{"pmid":"19445729","id":"PMC_19445729","title":"A dual role of Cdk2 in DNA damage response.","date":"2009","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/19445729","citation_count":61,"is_preprint":false},{"pmid":"25380821","id":"PMC_25380821","title":"CDK2 regulates nuclear envelope protein dynamics and telomere attachment in mouse meiotic prophase.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25380821","citation_count":59,"is_preprint":false},{"pmid":"9925749","id":"PMC_9925749","title":"Cyclin D1 inhibits cell proliferation through binding to PCNA and cdk2.","date":"1999","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/9925749","citation_count":59,"is_preprint":false},{"pmid":"19440053","id":"PMC_19440053","title":"Origin licensing and p53 status regulate Cdk2 activity during G(1).","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19440053","citation_count":59,"is_preprint":false},{"pmid":"38462150","id":"PMC_38462150","title":"Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.","date":"2024","source":"Critical reviews in oncology/hematology","url":"https://pubmed.ncbi.nlm.nih.gov/38462150","citation_count":58,"is_preprint":false},{"pmid":"25918937","id":"PMC_25918937","title":"Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.","date":"2015","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25918937","citation_count":57,"is_preprint":false},{"pmid":"7779716","id":"PMC_7779716","title":"Coexpression of cdk2/cdc2 and retinoblastoma gene products in colorectal cancer.","date":"1995","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7779716","citation_count":56,"is_preprint":false},{"pmid":"29507054","id":"PMC_29507054","title":"Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.","date":"2018","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/29507054","citation_count":55,"is_preprint":false},{"pmid":"20445224","id":"PMC_20445224","title":"Cdk2: a key regulator of the senescence control function of Myc.","date":"2010","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/20445224","citation_count":54,"is_preprint":false},{"pmid":"31804459","id":"PMC_31804459","title":"SKA3 Promotes tumor growth by regulating CDK2/P53 phosphorylation in hepatocellular carcinoma.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31804459","citation_count":54,"is_preprint":false},{"pmid":"1517236","id":"PMC_1517236","title":"Cdc25 regulates the phosphorylation and activity of the Xenopus cdk2 protein kinase complex.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1517236","citation_count":54,"is_preprint":false},{"pmid":"18256689","id":"PMC_18256689","title":"Cdk1 and Cdk2 activity levels determine the efficiency of replication origin firing in Xenopus.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18256689","citation_count":54,"is_preprint":false},{"pmid":"11175348","id":"PMC_11175348","title":"PKCeta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11175348","citation_count":54,"is_preprint":false},{"pmid":"18838553","id":"PMC_18838553","title":"Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18838553","citation_count":53,"is_preprint":false},{"pmid":"16479016","id":"PMC_16479016","title":"Protein phosphatase 2A antagonizes ATM and ATR in a Cdk2- and Cdc7-independent DNA damage checkpoint.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16479016","citation_count":52,"is_preprint":false},{"pmid":"35045293","id":"PMC_35045293","title":"WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35045293","citation_count":49,"is_preprint":false},{"pmid":"16285732","id":"PMC_16285732","title":"Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16285732","citation_count":49,"is_preprint":false},{"pmid":"31451657","id":"PMC_31451657","title":"Phenotypical microRNA screen reveals a noncanonical role of CDK2 in regulating neutrophil migration.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31451657","citation_count":48,"is_preprint":false},{"pmid":"24780297","id":"PMC_24780297","title":"Hexokinase 2 regulates G1/S checkpoint through CDK2 in cancer-associated fibroblasts.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24780297","citation_count":46,"is_preprint":false},{"pmid":"28376145","id":"PMC_28376145","title":"Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.","date":"2017","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/28376145","citation_count":43,"is_preprint":false},{"pmid":"8275715","id":"PMC_8275715","title":"Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes.","date":"1994","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8275715","citation_count":43,"is_preprint":false},{"pmid":"24586195","id":"PMC_24586195","title":"Mammalian E-type cyclins control chromosome pairing, telomere stability and CDK2 localization in male meiosis.","date":"2014","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24586195","citation_count":41,"is_preprint":false},{"pmid":"29323532","id":"PMC_29323532","title":"Identification of CDK2 as a novel target in treatment of prostate cancer.","date":"2018","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29323532","citation_count":41,"is_preprint":false},{"pmid":"20713526","id":"PMC_20713526","title":"Tipping the balance: Cdk2 enables Myc to suppress senescence.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20713526","citation_count":39,"is_preprint":false},{"pmid":"29570358","id":"PMC_29570358","title":"Long Noncoding RNA LINC00958 Accelerates Gliomagenesis Through Regulating miR-203/CDK2.","date":"2018","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29570358","citation_count":39,"is_preprint":false},{"pmid":"37270540","id":"PMC_37270540","title":"Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37270540","citation_count":38,"is_preprint":false},{"pmid":"26248649","id":"PMC_26248649","title":"miR-200c Targets CDK2 and Suppresses Tumorigenesis in Renal Cell Carcinoma.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/26248649","citation_count":38,"is_preprint":false},{"pmid":"19838212","id":"PMC_19838212","title":"DNA damage induces Chk1-dependent threonine-160 phosphorylation and activation of Cdk2.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19838212","citation_count":38,"is_preprint":false},{"pmid":"14657662","id":"PMC_14657662","title":"Cdk2 as a master of S phase entry: fact or fake?","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/14657662","citation_count":38,"is_preprint":false},{"pmid":"10196317","id":"PMC_10196317","title":"Functional interactions between herpesvirus oncoprotein MEQ and cell cycle regulator CDK2.","date":"1999","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10196317","citation_count":38,"is_preprint":false},{"pmid":"33526892","id":"PMC_33526892","title":"Allostery governs Cdk2 activation and differential recognition of CDK inhibitors.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33526892","citation_count":36,"is_preprint":false},{"pmid":"15922732","id":"PMC_15922732","title":"CDK2 translational down-regulation during endothelial senescence.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15922732","citation_count":36,"is_preprint":false},{"pmid":"10393546","id":"PMC_10393546","title":"Mechanism of Cdk2/Cyclin E inhibition by p27 and p27 phosphorylation.","date":"1999","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10393546","citation_count":36,"is_preprint":false},{"pmid":"16759374","id":"PMC_16759374","title":"Cdk2 and Cdk4 cooperatively control the expression of Cdc2.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/16759374","citation_count":35,"is_preprint":false},{"pmid":"12030783","id":"PMC_12030783","title":"Perspectives for cancer therapies with cdk2 inhibitors.","date":"2001","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/12030783","citation_count":34,"is_preprint":false},{"pmid":"35039060","id":"PMC_35039060","title":"SLCO4A1-AS1 promotes colorectal tumourigenesis by regulating Cdk2/c-Myc signalling.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/35039060","citation_count":34,"is_preprint":false},{"pmid":"27819669","id":"PMC_27819669","title":"A CDK2 activity signature predicts outcome in CDK2-low cancers.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27819669","citation_count":33,"is_preprint":false},{"pmid":"38818077","id":"PMC_38818077","title":"CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets.","date":"2024","source":"JACS Au","url":"https://pubmed.ncbi.nlm.nih.gov/38818077","citation_count":31,"is_preprint":false},{"pmid":"29063678","id":"PMC_29063678","title":"Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.","date":"2018","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29063678","citation_count":31,"is_preprint":false},{"pmid":"17361108","id":"PMC_17361108","title":"Autocatalytic phosphorylation of CDK2 at the activating Thr160.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17361108","citation_count":31,"is_preprint":false},{"pmid":"31267714","id":"PMC_31267714","title":"CDK1 and CDK2 regulate NICD1 turnover and the periodicity of the segmentation clock.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31267714","citation_count":30,"is_preprint":false},{"pmid":"27465546","id":"PMC_27465546","title":"miR-302b regulates cell cycles by targeting CDK2 via ERK signaling pathway in gastric cancer.","date":"2016","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27465546","citation_count":30,"is_preprint":false},{"pmid":"12239611","id":"PMC_12239611","title":"p27, cyclin E, and CDK2 expression in normal and cancerous endometrium.","date":"2002","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12239611","citation_count":30,"is_preprint":false},{"pmid":"24107632","id":"PMC_24107632","title":"SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways.","date":"2013","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/24107632","citation_count":30,"is_preprint":false},{"pmid":"34632667","id":"PMC_34632667","title":"Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34632667","citation_count":29,"is_preprint":false},{"pmid":"29033307","id":"PMC_29033307","title":"NEUROG1 Regulates CDK2 to Promote Proliferation in Otic Progenitors.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29033307","citation_count":29,"is_preprint":false},{"pmid":"27371320","id":"PMC_27371320","title":"Cdk2 catalytic activity is essential for meiotic cell division in vivo.","date":"2016","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/27371320","citation_count":29,"is_preprint":false},{"pmid":"12678910","id":"PMC_12678910","title":"Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.","date":"2003","source":"Current medicinal chemistry. Anti-cancer agents","url":"https://pubmed.ncbi.nlm.nih.gov/12678910","citation_count":27,"is_preprint":false},{"pmid":"35181784","id":"PMC_35181784","title":"CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses.","date":"2022","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35181784","citation_count":27,"is_preprint":false},{"pmid":"24704824","id":"PMC_24704824","title":"KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24704824","citation_count":27,"is_preprint":false},{"pmid":"33147476","id":"PMC_33147476","title":"Protein Dynamics Enables Phosphorylation of Buried Residues in Cdk2/Cyclin-A-Bound p27.","date":"2020","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/33147476","citation_count":27,"is_preprint":false},{"pmid":"39924553","id":"PMC_39924553","title":"Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39924553","citation_count":25,"is_preprint":false},{"pmid":"16191191","id":"PMC_16191191","title":"Biochemical characterization of Cdk2-Speedy/Ringo A2.","date":"2005","source":"BMC biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16191191","citation_count":25,"is_preprint":false},{"pmid":"19829063","id":"PMC_19829063","title":"Identification and characterization of CAC1 as a novel CDK2-associated cullin.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19829063","citation_count":24,"is_preprint":false},{"pmid":"25860957","id":"PMC_25860957","title":"ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25860957","citation_count":23,"is_preprint":false},{"pmid":"31431461","id":"PMC_31431461","title":"The Cdk2-c-Myc-miR-571 Axis Regulates DNA Replication and Genomic Stability by Targeting Geminin.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31431461","citation_count":23,"is_preprint":false},{"pmid":"17457058","id":"PMC_17457058","title":"CDK2 and FOXO1: a fork in the road for cell fate decisions.","date":"2007","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/17457058","citation_count":23,"is_preprint":false},{"pmid":"26464264","id":"PMC_26464264","title":"CK1δ activity is modulated by CDK2/E- and CDK5/p35-mediated phosphorylation.","date":"2016","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/26464264","citation_count":23,"is_preprint":false},{"pmid":"33075054","id":"PMC_33075054","title":"A novel function for CDK2 activity at meiotic crossover sites.","date":"2020","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/33075054","citation_count":22,"is_preprint":false},{"pmid":"36575184","id":"PMC_36575184","title":"SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis.","date":"2022","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36575184","citation_count":21,"is_preprint":false},{"pmid":"21262353","id":"PMC_21262353","title":"Compartmentalized CDK2 is connected with SHP-1 and β-catenin and regulates insulin internalization.","date":"2011","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21262353","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45068,"output_tokens":11004,"usd":0.150132,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22022,"output_tokens":6125,"usd":0.131617,"stage2_stop_reason":"end_turn"},"total_usd":0.281749,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"CDK2 activity is regulated by phosphorylation: Thr160 phosphorylation is required for kinase activity (T160A abolishes activity), while Tyr15 and Thr14 phosphorylation are inhibitory (mutation of Y15/T14 stimulates activity). CDC25 phosphatase activates CDK2 by dephosphorylating Y15/T14 in vitro.\",\n      \"method\": \"Site-directed mutagenesis, transient transfection in COS cells, in vitro phosphatase assay, cell cycle synchronization\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro assay combined with mutagenesis, replicated across multiple regulatory sites, consistent with parallel CDC2 findings\",\n      \"pmids\": [\"1396589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CDK2 phosphorylates the retinoblastoma protein (RB) in vitro at sites phosphorylated in vivo, and CDK2 forms a complex with RB in vitro. The timing of CDK2 activation correlates with onset of RB phosphorylation in the cell cycle.\",\n      \"method\": \"In vitro kinase assay with purified CDK2, co-precipitation/complex formation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution with purified protein, site correspondence confirmed, timing correlation in cells\",\n      \"pmids\": [\"1518810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Cyclin E and cyclin A each associate with CDK2 in a temporally distinct manner during the cell cycle: cyclin E/CDK2 appears in G1 and associates with E2F and p107, while cyclin A/CDK2 association with E2F becomes detectable as cells enter S phase.\",\n      \"method\": \"Immunoprecipitation with cyclin-specific antisera, cell cycle synchronization\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal immunoprecipitation across multiple human cell lines with cell cycle staging\",\n      \"pmids\": [\"1398067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"In Xenopus, CDK2 is regulated by periodic phosphorylation on tyrosine and serine residues during the cell cycle; CDC25 phosphatase dephosphorylates CDK2 at the major in vivo phosphorylation site and activates it in vitro.\",\n      \"method\": \"Phosphopeptide mapping, in vitro CDC25 dephosphorylation assay, immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with phosphopeptide mapping confirming site-specific dephosphorylation and activation\",\n      \"pmids\": [\"1517236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CDK2 is required for the G1-to-S phase transition in mammalian cells; microinjection of anti-CDK2 antibodies blocked cells from entering S phase, and the effect was abrogated by pre-adsorption with CDK2 protein. Cyclin E/CDK2 complex accounts for the majority of histone H1 kinase activity in late G1.\",\n      \"method\": \"Antibody microinjection into serum-stimulated quiescent human fibroblasts, immunoprecipitation/kinase assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function by antibody microinjection with specific rescue control, corroborated by kinase activity measurements\",\n      \"pmids\": [\"8502482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CDK2 kinase is required for activating the origin unwinding step of DNA replication; in CDK2-depleted Xenopus egg extracts, primer synthesis does not occur and RPA remains tightly associated with replication foci. Organization of chromatin into replication foci is CDK2-independent and precedes CDK2 activation.\",\n      \"method\": \"Cell-free Xenopus egg extract replication system, CDK2 immunodepletion, primer synthesis assay, RPA localization\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted cell-free system with immunodepletion and direct biochemical readouts\",\n      \"pmids\": [\"7698977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Cyclin E/CDK2 directly phosphorylates p27Kip1 at Thr187 in vitro and in vivo, leading to p27 elimination from the cell and allowing G1-to-S progression. Mutation of T187 to alanine creates a p27 resistant to cyclin E-driven degradation. p27 interacts with cyclin E/CDK2 in two ways: as a tight inhibitor (at low ATP) or as a substrate (at physiological ATP), governed by ATP binding to CDK2.\",\n      \"method\": \"In vitro kinase assay, mutagenesis (T187A), transient expression in murine fibroblasts, cell cycle analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, kinetic analysis, and in vivo validation in multiple cellular contexts\",\n      \"pmids\": [\"9192873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Ras and Myc cooperate to induce accumulation of active cyclin E-dependent CDK2 kinase activity and E2F target gene expression; this cooperative activation is associated with loss of the p27 CDK inhibitor. Ras alone is insufficient to induce cyclin E-CDK2 activity.\",\n      \"method\": \"Ras inhibition (dominant negative), Myc/Ras co-expression, CDK kinase assays, cell cycle analysis in Rb+/+ and Rb-/- fibroblasts\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with kinase activity measurement, single lab, multiple cell line contexts\",\n      \"pmids\": [\"9163430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p27 acts as a tight-binding inhibitor of CDK2/Cyclin E; CDK2/Cyclin E has ~60-fold higher specificity for pRb than histone H1. The CDK2/Cyclin E/p27 ternary complex is kinetically inactive as a kinase but serves as a substrate for CDK2/Cyclin E. p27 can be phosphorylated by CDK2/Cyclin E only at high enzyme concentrations.\",\n      \"method\": \"In vitro kinase assay with purified recombinant proteins (CAK-phosphorylated CDK2/Cyclin E, p27), kcat/Km determination, inhibition kinetics\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro reconstitution with purified proteins and quantitative kinetic analysis\",\n      \"pmids\": [\"10393546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p130 (Rb family member) directly substitutes for p27 and p21 as a CDK2 inhibitor in mitogen-starved fibroblasts; cyclin E-CDK2 kinase activity cannot be inhibited by mitogen starvation in cells lacking both p27 and p130.\",\n      \"method\": \"MEFs from p27/p21 double knockout mice, CDK2 activity assays, p130 identification as titratable CDK2 inhibitor\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic double knockout plus biochemical CDK2 activity measurement, single lab\",\n      \"pmids\": [\"10074425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Cyclin D1 forms complexes with PCNA and CDK2 in senescent cells; excess cyclin D1 inhibits CDK2 kinase activity and represses DNA replication in vitro. Overexpression of CDK2 or PCNA rescues the cyclin D1-mediated inhibition of DNA synthesis.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay (GST-cyclin D1), in vitro DNA replication assay, rescue by CDK2/PCNA overexpression\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro assay plus genetic rescue, single lab\",\n      \"pmids\": [\"9925749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PKCη associates with the cyclin E/CDK2/p21 complex in keratinocytes, phosphorylates p21 within the complex, and inhibits CDK2 kinase activity (measured by Rb phosphorylation). This is accompanied by dephosphorylation of Thr160 on CDK2.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, dominant-negative PKCη, immunofluorescence colocalization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with kinase assay and dominant-negative control, single lab\",\n      \"pmids\": [\"11175348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RINGO (Speedy) activates CDK2 independently of Thr160 phosphorylation; CDK2-RINGO complexes are less susceptible to inhibition by p21 than cyclin-bound CDK2. RINGO can bind and stimulate CDK2 kinase activity without the T-loop phosphorylation required for cyclin-activated CDK2.\",\n      \"method\": \"In vitro kinase assays with RINGO-CDK2 complexes, T161A mutagenesis, p21 inhibition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis demonstrating mechanistic independence from canonical activation pathway\",\n      \"pmids\": [\"11461916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CDK2 knockout mice are viable but sterile; Cdk2 is required for germ cell development and meiosis. In Cdk2-/- cells, cyclin E1 immunoprecipitates show no kinase activity toward histone H1. CDK2 loss affects the timing of S phase entry but does not prevent cell proliferation, with cyclin A2 complexes maintaining activity.\",\n      \"method\": \"Gene knockout mice, immunoprecipitation/kinase assay, cell cycle analysis, MEF proliferation assays, ectopic CDK2 re-expression rescue\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complete gene knockout with biochemical validation, rescue experiment, replicated phenotype across multiple tissues\",\n      \"pmids\": [\"14561402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CDK2 is dispensable for proliferation in multiple cancer cell types (colon cancer, osteosarcoma, Rb-negative cervical cancers); inhibition of CDK2 by dominant-negative CDK2, antisense oligonucleotides, or siRNA did not prevent cell proliferation in these cells.\",\n      \"method\": \"Dominant-negative CDK2 expression, antisense oligonucleotides, siRNA knockdown, cell proliferation assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple independent loss-of-function approaches in multiple cell lines, single lab, negative finding\",\n      \"pmids\": [\"12676582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CDK2 is a genuine client of the Hsp90/Cdc37 chaperone complex; disruption of helix αC of CDK2 disrupts Hsp90 and Cdc37 binding. The G-box motif of CDK2 is critical for Cdc37 binding, while helix αC and stabilization of helix αE are required for Hsp90 binding.\",\n      \"method\": \"Pull-down assays, Hsp90 inhibitor (geldanamycin) treatment, deletion mutagenesis, molybdate stabilization\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pull-down approaches with mutagenesis, single lab\",\n      \"pmids\": [\"16285732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Biochemical characterization of CDK2-Speedy/Ringo A2 shows it has broad substrate specificity (unlike the canonical (S/T)PX(K/R) preference of CDK2-cyclin A), phosphorylates Cdc25 proteins nearly as well as CDK2-cyclin A at non-canonical sites, and its activity and substrate recognition are not significantly affected by Thr160 phosphorylation. CDK2-Speedy/Ringo A2 is not a substrate for metazoan CAK.\",\n      \"method\": \"In vitro kinase assays with purified proteins, phosphopeptide mapping, CAK phosphorylation assay, Thr160A mutagenesis\",\n      \"journal\": \"BMC biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro reconstitution with quantitative substrate profiling and mutagenesis\",\n      \"pmids\": [\"16191191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cdk2 and Cdk4 cooperate to phosphorylate Rb in vivo; Cdk2-/-Cdk4-/- double knockout mice die embryonically (~E15) with progressive reduction of Rb phosphorylation and reduced E2F-target gene expression. HPV-E7 inactivation of Rb rescues DKO MEF phenotypes (senescence, proliferation), but p27 loss does not.\",\n      \"method\": \"Double knockout mice, western blot for Rb phosphorylation, MEF proliferation/senescence assays, genetic epistasis with HPV-E7 and p27 knockout\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double genetic knockout with epistasis rescue experiments, multiple orthogonal readouts\",\n      \"pmids\": [\"16678773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CDK2 directly phosphorylates FOXO1 at Ser249 in vitro and in vivo, causing cytoplasmic localization and inhibition of FOXO1. This phosphorylation is abrogated upon DNA damage through the Chk1/Chk2 checkpoint pathway. CDK2-mediated inhibition of FOXO1 regulates apoptotic cell death after DNA strand breakage.\",\n      \"method\": \"In vitro kinase assay, in vivo phosphorylation, siRNA knockdown, subcellular localization assays, checkpoint kinase inhibition\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro phosphorylation with in vivo validation, localization consequence demonstrated, pathway epistasis established\",\n      \"pmids\": [\"17038621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CDK2 is capable of autophosphorylation at Thr160; bacterially expressed monomeric CDK2 is phosphorylated at Thr160 and exhibits kinase activity toward histone H1 that is stimulated by cyclin E or A. Pharmacological CDK2 inhibition or co-expression of p21/p27 inhibits Thr160 phosphorylation in human cells.\",\n      \"method\": \"Bacterial expression/purification, mass spectrometry phosphopeptide mapping, mutagenesis (K33R, T160A), lambda phosphatase treatment, CDK2 inhibitor treatment in cells\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mass spectrometry confirmation and mutagenesis, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"17361108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CDK2 phosphorylates SMRT transcriptional corepressor at multiple sites, creating a phosphorylation-dependent binding site for the Pin1 prolyl isomerase, which decreases SMRT protein stability and affects SMRT-dependent transcriptional repression. Her2/Neu/ErbB2 signaling functions upstream of both Pin1 and CDK2 to regulate SMRT stability.\",\n      \"method\": \"Co-immunoprecipitation (in vitro and in mammalian cells), mutagenesis of phosphorylation sites, protein stability assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP in vitro and in cells, mutagenesis validation, single lab\",\n      \"pmids\": [\"18838553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Both Cdk1 and Cdk2 are necessary for efficient DNA replication in Xenopus egg extracts by controlling origin activation frequency; Cdk2/cyclin E contributes more to origin cluster efficiency than Cdk1/cyclin A. CDK activity controls the pre-replication complex to pre-initiation complex transition at low activity levels.\",\n      \"method\": \"Protein depletion and selective chemical inhibition in Xenopus egg extracts, DNA replication and origin spacing analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cell-free reconstitution with independent depletion and chemical inhibition approaches\",\n      \"pmids\": [\"18256689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DNA damage induces Chk1-dependent activating T160 phosphorylation of CDK2 and increases CDK2 activity; this CDK2 upregulation promotes centrosome amplification after ionizing radiation. CDK1 can substitute for CDK2 in IR-induced centrosome amplification. T160A mutation blocks CDK2-mediated rescue of centrosome amplification.\",\n      \"method\": \"CDK2-/- and Chk1-/- DT40 cells, kinase activity assays, immunofluorescence, CDK2 T160A mutagenesis, rescue experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockouts with mutagenesis-based rescue, multiple cell line validation, pathway epistasis\",\n      \"pmids\": [\"19838212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Depletion of origin licensing factors (Cdc6 or Cdt1) inhibits cyclin E/CDK2 activity in normal cells through reduction of activating T160 phosphorylation and delayed nuclear CDK2 accumulation; this Cdk2 inhibition requires p53. CDK2 activity is uncoupled from origin licensing in p53-deficient cancer cells.\",\n      \"method\": \"siRNA depletion, CDK2 kinase assay, T160 phosphorylation western blot, CDK2 subcellular fractionation, p53 co-depletion epistasis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple depletion approaches with biochemical CDK2 readouts, p53 epistasis, single lab\",\n      \"pmids\": [\"19440053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CDK2 has a non-catalytic function in restricting assembly of cyclin A with CDK1; a sensitizing mutation in CDK2 impaired this function, which could be corrected by both inhibitory and non-inhibitory bulky adenine analogs. Chemical-genetic approach revealed CDK2 activity is required for restriction point passage and S phase entry in human cells.\",\n      \"method\": \"Chemical genetics with analog-sensitive CDK2 allele, bulky adenine analog inhibition and rescue, cell cycle analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — analog-sensitive allele approach with orthogonal chemical tools, distinguishes catalytic from non-catalytic CDK2 functions\",\n      \"pmids\": [\"21658603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDK2 activity bifurcates at mitotic exit to control the proliferation-quiescence decision: cells either immediately build up CDK2 activity (commit to next cycle) or suppress CDK2 activity and enter transient quiescence (G0-like state). This bifurcation is directly controlled by the CDK inhibitor p21, and regulated by mitogens during a restriction window at the end of the previous cell cycle.\",\n      \"method\": \"Live-cell CDK2 activity sensor, single-cell imaging, p21 manipulation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live-cell CDK2 biosensor with loss-of-function validation, mechanistic pathway placement\",\n      \"pmids\": [\"24075009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CDK2 ablation combined with cyclin A2 loss strongly suppresses tumor formation in oncogene-transformed MEFs, associated with decreased proliferation, premature senescence, and failure of compensatory Cdk1 activity increase (which occurs with cyclin A2 loss alone).\",\n      \"method\": \"Conditional double knockout mice, oncogene-transformed MEF tumor formation assays, Cdk1 kinase activity measurement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional double genetic knockout with tumor assay and compensatory kinase measurement, single lab\",\n      \"pmids\": [\"24802190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CDK2 is required for nuclear envelope dynamics and telomere attachment during mouse meiotic prophase I; CDK2 ablation causes abnormal distribution of SUN1, KASH5, and lamin C2 in spermatocytes, and some telomeres fail to attach to the nuclear envelope. Mouse testis CDK2 phosphorylates SUN1 in vitro.\",\n      \"method\": \"Immunofluorescence and electron microscopy of Cdk2-/- spermatocytes, in vitro kinase assay with SUN1 substrate\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout phenotype with in vitro kinase substrate validation, single lab\",\n      \"pmids\": [\"25380821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Wild-type CDK2 can bind type II inhibitors that target the DFG-out (inactive) conformation; type II inhibitors compete with binding of activating cyclins to CDK2. Key residues distant from the ATP-binding pocket modulate the energetics of the DFG-out transition.\",\n      \"method\": \"Site-directed mutagenesis, protein crystallography (first CDK2/type II inhibitor co-crystal structure), biochemical/biophysical inhibitor binding assays\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis and binding kinetics, demonstrates novel inhibitor binding mode\",\n      \"pmids\": [\"26158339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"An irreversible CDK2 inhibitor (NU6300) binds covalently to CDK2, confirmed by co-complex crystal structure. Acute treatment produced durable inhibition of Rb phosphorylation in cells, consistent with irreversible CDK2 inhibition.\",\n      \"method\": \"Crystal structure of CDK2/NU6300 covalent complex, cell-based Rb phosphorylation assay\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure of covalent complex with cellular validation, single lab\",\n      \"pmids\": [\"26320860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CDK2 catalytic activity is essential for meiotic cell division in vivo; kinase-dead CDK2 knockin mice (D145N or T160A) are sterile with defective meiosis, identical to Cdk2 knockout mice. These point mutant mice show normal mitotic cell cycle progression, demonstrating the meiotic function is specifically kinase-activity-dependent.\",\n      \"method\": \"Knockin mouse generation (D145N, T160A point mutations), phenotypic analysis, cell cycle analysis in MEFs, reproductive organ analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent kinase-dead knockin alleles with identical meiotic sterility phenotype, distinguishes catalytic from non-catalytic functions\",\n      \"pmids\": [\"27371320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK2 has a non-canonical role in regulating neutrophil migration and cell polarity, independent of its cell cycle functions; CDK2 inhibition or knockdown disrupts neutrophil chemotaxis and polarization without inducing cell death, and alters downstream formyl peptide receptor signaling in terminally differentiated neutrophils.\",\n      \"method\": \"miRNA screen in zebrafish, CDK2 inhibition and siRNA knockdown in zebrafish and human neutrophil-like cells, chemotaxis assay, cell polarity imaging\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple loss-of-function approaches in two model systems with defined cellular phenotype, single lab\",\n      \"pmids\": [\"31451657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK1 and CDK2 phosphorylate Notch intracellular domain (NICD1) in a domain required for SCF E3 ligase recognition; inhibiting CDK1 or CDK2 increases NICD1 levels in vitro and in vivo and delays segmentation clock oscillation period.\",\n      \"method\": \"In vitro kinase assay with CDK1 and CDK2, CDK inhibitor treatment in vivo, NICD1 protein level measurement, clock period analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay combined with in vivo CDK inhibitor effects, single lab\",\n      \"pmids\": [\"31267714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK2 localizes to late recombination nodules (LRNs) at meiotic crossover sites; elevated CDK2 activity increases MLH1 focus numbers at LRNs but not crossover numbers, while reduced CDK2 activity abolishes crossover formation entirely during meiotic prophase I.\",\n      \"method\": \"CDK2 activity point mutant knockin mice (elevated/reduced activity), immunofluorescence of LRN proteins, crossover analysis\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two activity-modulating knockin alleles with quantitative meiotic phenotype analysis, single lab\",\n      \"pmids\": [\"33075054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Allosteric coupling between CDK2 regulatory phosphorylation (Thr160) and cyclin binding explains CDK2 activation; monomeric CDK2 samples an active-like state but lacks activity; T-loop phosphorylation enhances allosteric coupling with cyclin. An allosteric hub diverged between CDK2 and CDK4 governs the strength of allosteric coupling and differential inhibitor recognition.\",\n      \"method\": \"Solution biophysics, thermodynamic modeling, NMR/EPR spectroscopy, functional assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple biophysical methods with thermodynamic modeling establish allosteric mechanism of CDK2 activation\",\n      \"pmids\": [\"33526892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mitochondrial ROS promote CDK2 T-loop (Thr160) phosphorylation and full CDK2 activation during S phase by oxidizing a conserved cysteine residue near the T-loop, which prevents binding of the T-loop phosphatase KAP, thereby coupling mitochondrial metabolism to DNA replication via CDK2.\",\n      \"method\": \"Chemical/metabolic ROS interference, live-cell CDK2 activity reporters, phosphorylation assays, cysteine mutagenesis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal interference methods with mechanistic identification of cysteine oxidation preventing KAP binding\",\n      \"pmids\": [\"35809563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Disrupting the CDK2/Cyclin A protein-protein interaction (PPI) with homoharringtonine (HHT) induces autophagic degradation of CDK2 via Trim21 E3 ubiquitin ligase in cancer cells, confirmed in a leukemia mouse model.\",\n      \"method\": \"In silico PPI pocket screening, protein interaction disruption assay, CDK2 degradation assay, Trim21 identification, leukemia mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — PPI disruption with identification of E3 ligase mediating CDK2 autophagic degradation, validated in mouse model, single lab\",\n      \"pmids\": [\"35595767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CDK2 inhibition reduces RB phosphorylation, decreases E2F-mediated DNMT1 transcription, and increases endogenous retroviral RNA expression and type I IFN response, enhancing antitumor immunity through increased antigen presentation and CD8+ T-cell infiltration.\",\n      \"method\": \"CDK2 small molecule inhibitors, genetic Cdk2 deficiency in murine tumor models, IFN response measurement, T-cell infiltration analysis\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological CDK2 loss-of-function with mechanistic pathway (RB→E2F→DNMT1→ERV→IFN), single lab\",\n      \"pmids\": [\"35181784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"WEE1 kinase protects stalled DNA replication forks by suppressing CDK2 activity; CDK2 suppression is the major WEE1-dependent activity counteracting fork degradation, and DNA2 nuclease is responsible for excessive fork degradation in WEE1-inhibited cells.\",\n      \"method\": \"WEE1 inhibition, CDK2 inhibition, DNA fiber assays, DNA2 knockdown epistasis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis between WEE1, CDK2, and DNA2 with defined fork degradation phenotype, single lab\",\n      \"pmids\": [\"35045293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SARS-CoV-2 nsp12 (RdRp) interacts with host CDK2; CDK2 phosphorylates nsp12 at Thr20, facilitating assembly of the RdRp complex (nsp12/nsp7/nsp8) and promoting viral RNA synthesis. CDK2 inhibitors impair viral RNA synthesis and SARS-CoV-2 infection.\",\n      \"method\": \"Mass spectrometry-based proteomics, Co-IP, in vitro phosphorylation assay, CDK2 inhibitor treatment, viral RNA measurement\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vitro phosphorylation with functional viral RNA readout, single lab\",\n      \"pmids\": [\"36575184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Upon acute CDK2 inhibition, CDK4/6 activity backstops CDK2 by maintaining Rb1 hyperphosphorylation, active E2F transcription, and cyclin A2 expression, enabling re-activation of CDK2 in the presence of drug. CDK1 does not compensate for acute CDK2 inhibition (unlike in Cdk2-/- mice). Co-inhibition of CDK2 and CDK4/6 is required to suppress adaptation.\",\n      \"method\": \"Multiple CDK2 inhibitors, phosphoproteomics of CDK2 substrates, cell cycle analysis, combination drug treatment\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple CDK2 inhibitors with phosphoproteomic substrate tracking and genetic/pharmacological epistasis, mechanistic drug adaptation pathway defined\",\n      \"pmids\": [\"37267950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Type III allosteric CDK2 inhibitors (anthranilic acid series) bind CDK2 with nanomolar affinity and exhibit strong negative cooperativity with cyclin binding, providing CDK2 selectivity over CDK1. These inhibitors recapitulate Cdk2-/- meiotic phenotypes in testicular explants.\",\n      \"method\": \"Crystal structure, biophysical binding assays, cellular CDK2 activity assays, mouse testicular explant phenotypic assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure confirming allosteric binding mode, biophysical cooperativity measurements, in vitro and ex vivo functional validation\",\n      \"pmids\": [\"37270540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Endosomal CDK2 associates with SHP-1 phosphatase and β-catenin in hepatic endosome fractions; CDK2 phosphorylates β-catenin (but not CEACAM1), and partial CDK2 downmodulation increases insulin internalization rate, placing CDK2 in a Cdk2/SHP-1/β-catenin/CEACAM1 axis regulating insulin internalization.\",\n      \"method\": \"Subcellular fractionation, Triton X-100 resistance assay, co-immunoprecipitation, CDK2 knockdown, insulin internalization assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP plus knockdown with functional readout, substrate assignment not fully confirmed by in vitro reconstitution, single lab\",\n      \"pmids\": [\"21262353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CAC1 (Cdk-Associated Cullin1), a novel cullin-domain protein, physically associates with CDK2 and promotes CDK2 kinase activity; CAC1 knockdown by RNAi inhibits cell proliferation and induces G1/S arrest.\",\n      \"method\": \"Co-immunoprecipitation, CDK2 kinase activity assay after CAC1 knockdown, RNAi, cell cycle analysis\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP and kinase assay, mechanism of CDK2 activation by CAC1 not fully characterized, single lab\",\n      \"pmids\": [\"19829063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CDK2/Cyclin E and CDK2/Cyclin A phosphorylate ING5 at Thr152 in vitro; this phosphorylation occurs in cells in a cell cycle-dependent manner, and is enhanced by cyclin E/CDK2 overexpression and repressed by p27KIP1.\",\n      \"method\": \"In vitro kinase assay, phosphosite mutagenesis, cell cycle-dependent phosphorylation analysis, CDK2/cyclin overexpression and p27 inhibition\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis confirmed in cells, single lab\",\n      \"pmids\": [\"25860957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CDK2/Cyclin E phosphorylates CK1δ at its C-terminal domain, and this phosphorylation reduces CK1δ activity in vitro; pre-incubation of CK1δ with CDK2/E reduces CK1δ activity, and CDK inhibition with dinaciclib increases CK1δ activity in pancreatic cancer cells.\",\n      \"method\": \"In vitro kinase assay, CK1δ activity assay after CDK2/E phosphorylation, CDK inhibitor treatment in cells\",\n      \"journal\": \"Amino acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro phosphorylation with activity consequence validated in cells, single lab\",\n      \"pmids\": [\"26464264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK2 phosphorylates c-Myc at Serine 62 at the beginning of S phase, promoting c-Myc association with the miR-571 promoter and suppressing miR-571 expression to prevent aberrant DNA rereplication; this Cdk2-c-Myc-miR-571 axis regulates DNA replication and genomic stability.\",\n      \"method\": \"ChIP assay, c-Myc phospho-Ser62 detection, miR-571 promoter reporter, CDK2 inhibition and overexpression\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple approaches linking CDK2 phosphorylation of c-Myc to promoter binding and miRNA regulation, single lab\",\n      \"pmids\": [\"31431461\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDK2 is a serine/threonine kinase that requires binding of a cyclin (E or A) and activating phosphorylation at Thr160 (by CAK or autocatalysis) for full activity, while inhibitory phosphorylation at Thr14/Tyr15 (reversed by CDC25 phosphatases) suppresses it; the cyclin E/CDK2 complex drives G1/S transition by phosphorylating RB and p27 (at T187, targeting it for degradation), while cyclin A/CDK2 promotes S phase and DNA replication, and CDK2 activity is additionally regulated by the CDK inhibitors p21 and p27, by allosteric coupling between the T-loop and cyclin binding, by ROS-mediated oxidation of a conserved cysteine that prevents KAP phosphatase binding, and by the Hsp90/Cdc37 chaperone complex; CDK2 is non-redundantly required for meiosis (through its kinase activity) via roles in telomere–nuclear envelope attachment and meiotic crossover formation, and has non-canonical roles including phosphorylation of FOXO1 (linking DNA damage to apoptosis), SMRT, SUN1, NICD1, c-Myc (Ser62), and ING5, regulation of neutrophil migration, and control of endosomal insulin internalization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CDK2 is a cyclin-dependent serine/threonine kinase that drives the G1-to-S transition and DNA replication in the mammalian cell cycle [#4, #5]. Its activity requires association with cyclin E (in G1) or cyclin A (at S-phase entry) and is gated by phosphorylation: activating phosphorylation at Thr160 — installed by autophosphorylation or chaperone-assisted maturation as an Hsp90/Cdc37 client [#19, #15] — is required for catalysis, while inhibitory Thr14/Tyr15 phosphorylation suppresses it and is reversed by CDC25 phosphatase [#0, #3]. Activation reflects allosteric coupling between T-loop phosphorylation and cyclin binding, with monomeric CDK2 sampling an active-like but inactive state until cyclin engagement strengthens this coupling [#34]. Once active, cyclin E/CDK2 phosphorylates the retinoblastoma protein to relieve E2F repression and phosphorylates p27Kip1 at Thr187 to trigger its degradation, coupling mitogenic signaling to S-phase commitment [#1, #6, #2]; CDK2 activity at the licensed origin is required for origin unwinding and primer synthesis [#5, #21]. CDK2 activity is held in check by the CIP/KIP inhibitors p21 and p27, which can act either as tight-binding inhibitors or substrates depending on enzyme and ATP levels, and the level of CDK2 activity at mitotic exit — set by p21 — bifurcates cells into proliferation or quiescence [#8, #6, #25]. CDK2 is non-redundant for meiosis: kinase-dead knockin mice are sterile with intact mitosis, and CDK2 controls telomere–nuclear envelope attachment (phosphorylating SUN1) and meiotic crossover formation at late recombination nodules [#30, #27, #33]. Beyond the canonical cycle, CDK2 phosphorylates a range of substrates including FOXO1 (linking DNA damage to apoptotic control), c-Myc at Ser62, SMRT, NICD1, ING5 and CK1δ, and has cell-cycle-independent roles in neutrophil chemotaxis [#18, #46, #20, #32, #31]. CDK2 is largely dispensable for proliferation of many cancer cells because CDK1, CDK4/6, and cyclin A redundancy can compensate, a redundancy that also underlies adaptation to CDK2 inhibitors [#14, #17, #40].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Established how CDK2 catalytic output is switched on and off, defining the dual phosphorylation logic that gates a cell-cycle kinase.\",\n      \"evidence\": \"Site-directed mutagenesis and in vitro phosphatase assays in human and Xenopus systems mapping activating Thr160 and inhibitory Thr14/Tyr15 sites reversed by CDC25\",\n      \"pmids\": [\"1396589\", \"1517236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the activating Thr160 kinase (CAK) in these experiments\", \"Upstream control of CDC25 toward CDK2 not addressed\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Connected CDK2 to the RB/E2F machinery and showed cyclin E versus cyclin A partner cyclins act in temporally distinct windows, placing CDK2 at the G1/S control point.\",\n      \"evidence\": \"In vitro kinase assays with purified CDK2 against RB and cell-cycle-staged immunoprecipitation of cyclin E/A complexes with E2F/p107\",\n      \"pmids\": [\"1518810\", \"1398067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal requirement for CDK2 in vivo not yet demonstrated\", \"Functional consequence of RB phosphorylation on E2F release not shown here\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrated CDK2 is functionally required for entry into S phase, moving it from correlation to causation.\",\n      \"evidence\": \"Microinjection of anti-CDK2 antibodies into quiescent fibroblasts with antigen pre-adsorption rescue and kinase activity measurement\",\n      \"pmids\": [\"8502482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not distinguish cyclin E from cyclin A complex contributions\", \"Critical S-phase substrates not identified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the specific replication step requiring CDK2, showing it acts at origin unwinding/initiation rather than chromatin organization.\",\n      \"evidence\": \"CDK2 immunodepletion in Xenopus egg extracts with primer synthesis and RPA localization readouts\",\n      \"pmids\": [\"7698977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct replication-machinery substrates of CDK2 not identified\", \"Relative contribution of CDK1 not addressed in this study\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved how CDK2 escapes its own inhibitor, establishing the feed-forward p27-Thr187 phosphodegron and the substrate-versus-inhibitor duality of CIP/KIP proteins.\",\n      \"evidence\": \"In vitro kinase assays with T187A mutagenesis, ATP-dependent kinetics, and expression in fibroblasts; Ras/Myc cooperation linked to p27 loss and CDK2 activation\",\n      \"pmids\": [\"9192873\", \"9163430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase mediating p27 degradation not characterized here\", \"Mechanism of the ATP-dependent inhibitor-to-substrate switch left open\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Quantified CDK2 substrate preference and inhibitor stoichiometry, and identified redundant inhibitors (p130, cyclin D1) that buffer CDK2 activity.\",\n      \"evidence\": \"In vitro kinetics with purified CAK-phosphorylated CDK2/cyclin E, p27 inhibition assays, p27/p21 double-knockout MEFs, and cyclin D1/PCNA co-IP\",\n      \"pmids\": [\"10393546\", \"10074425\", \"9925749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of cyclin D1-CDK2-PCNA complex limited to senescent context\", \"Redundancy hierarchy among inhibitors in normal cells unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Revealed that CDK2 can be activated through a non-canonical, Thr160-independent route, expanding the modes of CDK2 control.\",\n      \"evidence\": \"In vitro reconstitution of RINGO/Speedy–CDK2 complexes with T-loop mutagenesis and p21 inhibition assays; later substrate profiling showed broad specificity and CAK independence\",\n      \"pmids\": [\"11461916\", \"16191191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contexts where RINGO activation dominates not defined\", \"Endogenous RINGO–CDK2 substrate set in cells not mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Genetic ablation overturned the view of CDK2 as essential for the mitotic cycle, revealing dispensability for proliferation but absolute requirement for meiosis.\",\n      \"evidence\": \"Cdk2 knockout mice and cancer-cell loss-of-function (dominant-negative, antisense, siRNA) with kinase and proliferation assays\",\n      \"pmids\": [\"14561402\", \"12676582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of compensation not yet identified in 2003\", \"Meiotic substrates of CDK2 not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified the compensating kinases and a DNA-damage-linked substrate, explaining CDK2 redundancy in mitosis and a non-canonical apoptotic role.\",\n      \"evidence\": \"Cdk2/Cdk4 double-knockout mice with RB phosphorylation and E2F readouts plus HPV-E7/p27 epistasis; in vitro and in vivo FOXO1-Ser249 phosphorylation with checkpoint epistasis\",\n      \"pmids\": [\"16678773\", \"17038621\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative apportioning of RB phosphorylation between CDK2 and CDK4 unclear\", \"How Chk1/Chk2 suppress CDK2 toward FOXO1 mechanistically not detailed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed CDK2 controls replication origin activation frequency in concert with CDK1 and extended the substrate repertoire to transcriptional corepressors.\",\n      \"evidence\": \"Depletion and chemical inhibition in Xenopus egg extracts with origin spacing analysis; SMRT phosphorylation creating Pin1 docking sites by co-IP and mutagenesis\",\n      \"pmids\": [\"18256689\", \"18838553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct origin-firing substrates of CDK2 not identified\", \"Generality of SMRT regulation across cell types untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linked CDK2 T160 activation to genome-surveillance signals — DNA damage, origin licensing, and p53 — establishing checkpoint-coupled control of CDK2.\",\n      \"evidence\": \"CDK2-/- and Chk1-/- DT40 cells with T160A rescue (centrosome amplification); siRNA depletion of licensing factors with p53 epistasis and CDK2 kinase/fractionation readouts; CAC1 co-IP\",\n      \"pmids\": [\"19838212\", \"19440053\", \"19829063\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CAC1-CDK2 activation mechanism is a single Co-IP without reconstitution\", \"How licensing status is transduced to T160 phosphorylation not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Distinguished catalytic from non-catalytic CDK2 functions and uncovered an endosomal signaling role, broadening CDK2 beyond a cell-cycle kinase.\",\n      \"evidence\": \"Analog-sensitive CDK2 allele with bulky adenine analogs for restriction-point passage and CDK1/cyclin A restriction; endosomal fractionation/Co-IP and knockdown for the SHP-1/β-catenin insulin-internalization axis\",\n      \"pmids\": [\"21658603\", \"21262353\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"β-catenin substrate assignment rests on Co-IP and knockdown without in vitro reconstitution (Low-confidence endosomal arm)\", \"Structural basis of the non-catalytic cyclin A/CDK1 restriction function unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that CDK2 catalytic activity, not the protein per se, drives meiosis and identified additional cell-cycle substrates.\",\n      \"evidence\": \"Kinase-dead (D145N, T160A) knockin mice with meiotic sterility but normal mitosis; in vitro/in-cell phosphorylation of ING5-Thr152 and CK1δ\",\n      \"pmids\": [\"27371320\", \"25860957\", \"26464264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Meiotic substrates accounting for sterility not fully enumerated\", \"Physiological impact of ING5/CK1δ phosphorylation in normal tissues limited\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined CDK2's role in the proliferation-quiescence decision and showed its loss, combined with cyclin A2, suppresses tumorigenesis.\",\n      \"evidence\": \"Live-cell CDK2 activity sensor with single-cell imaging and p21 manipulation; conditional Cdk2/cyclin A2 double knockout in oncogene-transformed MEF tumor assays\",\n      \"pmids\": [\"24075009\", \"26464264\", \"24802190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream determinants of the bifurcation beyond p21 not fully mapped\", \"Whether the quiescence decision involves the same substrates as proliferation unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided the biophysical mechanism of CDK2 activation and metabolic coupling, explaining how cyclin binding, T160 phosphorylation, and redox state converge on activity.\",\n      \"evidence\": \"Solution biophysics, NMR/EPR and thermodynamic modeling of allosteric T-loop/cyclin coupling; ROS/cysteine-oxidation interference with live-cell CDK2 reporters showing blockade of KAP phosphatase binding\",\n      \"pmids\": [\"33526892\", \"35809563\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of the allosteric hub divergence between CDK2/CDK4 not tested functionally\", \"Source and timing of the S-phase ROS signal not fully defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Expanded CDK2 into replication-stress, immune, and host-pathogen contexts and revealed its targetability through PPI disruption and degradation.\",\n      \"evidence\": \"WEE1/CDK2/DNA2 epistasis by DNA fiber assays; CDK2-RB-E2F-DNMT1-ERV-IFN pathway via genetic/pharmacological loss; CDK2 phosphorylation of SARS-CoV-2 nsp12-Thr20; HHT-induced Trim21-mediated autophagic CDK2 degradation; c-Myc-Ser62/miR-571 axis\",\n      \"pmids\": [\"35045293\", \"35181784\", \"36575184\", \"35595767\", \"31431461\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Several substrate/pathway assignments derive from single labs without reciprocal validation\", \"Direct fork-protection substrate downstream of CDK2 not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved how cells adapt to CDK2 inhibition and validated allosteric, cyclin-cooperative inhibitors with CDK2 selectivity.\",\n      \"evidence\": \"Multiple CDK2 inhibitors with substrate phosphoproteomics showing CDK4/6 backstopping; crystal structures of type II, covalent, and type III allosteric inhibitors with cooperativity measurements and testicular-explant phenotyping\",\n      \"pmids\": [\"37267950\", \"26158339\", \"26320860\", \"37270540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability of combination CDK2/CDK4/6 inhibition in vivo not fully established\", \"Selectivity determinants against CDK1 only partially mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The full set of physiological CDK2 substrates underlying its non-redundant meiotic function and its cell-cycle-independent roles (e.g., neutrophil migration) remains to be defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Meiotic crossover and telomere-attachment substrates beyond SUN1 not enumerated\", \"Mechanism by which CDK2 controls neutrophil polarity/FPR signaling unknown\", \"How context selects canonical versus non-canonical CDK2 substrate sets unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 6, 18, 27, 32, 44, 45, 46]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 6, 19]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [6, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [23, 27]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [42]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 25, 24]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [5, 21, 38]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [13, 30, 33]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [18, 22]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 2, 20]}\n    ],\n    \"complexes\": [\n      \"cyclin E/CDK2\",\n      \"cyclin A/CDK2\",\n      \"Hsp90/Cdc37 chaperone complex\"\n    ],\n    \"partners\": [\n      \"CCNE1\",\n      \"CCNA2\",\n      \"CDKN1B\",\n      \"CDKN1A\",\n      \"RB1\",\n      \"CDC25\",\n      \"CDC37\",\n      \"HSP90\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}